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Abstract 
The traditional herbal medicinal product Myrrhinil-Intest® is a fixed herbal combination, which 
is marketed in Germany since 1959 and applied in medical practice for the treatment of 
gastrointestinal disorders such as functional diarrhea, irritable bowel syndrome and 
inflammatory bowel disease. It contains myrrh, which is described as the oleo-gum resin from 
mainly Commiphora molmol Engler (Burseraceae), coffee charcoal, which are the milled 
roasted to blackening outer seed parts of green dried Coffea Arabica Linné (Rubiaceae) fruits 
and chamomile flowers - the flower heads of Matricaria recutita Linné (Asteraceae). The clinical 
effectiveness of Myrrhinil-Intest® for the treatment of various gastrointestinal disorders was 
demonstrated in several clinical studies and is described in various experience reports, 
however its pharmacological profile is not fully elucidated. Within the present study the 
spasmolytic and anti-inflammatory potential of the components myrrh, chamomile and coffee 
charcoal was investigated. Therefore pharmacological, histological and molecular biological 
methods were utilised. Spasmolytic activity was characterised using isometric tension 
measurement with rat isolated small intestinal preparations. Anti-inflammatory potential was 
assessed with different methods using isolated rat small intestinal preparations and immune 
cell lines. Inflammation was induced with TNBS and LPS respectively. Additionally, the 
influence of the herbal components on the gene expression profile of native human 
macrophages after LPS/IFNγ stimulation was determined by microarray gene expression 
analysis. Chamomile flower and myrrh exerted spasmolytic effects, whereby the more 
pronounced spasmolytic effects of myrrh were mediated via calcium channel blockade. Myrrh 
and chamomile flower exerted anti-inflammatory effects. 
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1 Introduction 
1.1 Functional bowel disorders and irritable bowel syndrome 
Functional bowel disorders are gastrointestinal disorders with symptoms attributable to the 
middle or lower gastrointestinal tract, which occur despite the absence of a structural or 
biochemical disorder. They include irritable bowel syndrome (IBS), functional bloating, 
functional constipation, functional diarrhea and unspecific bowel disorders (Longstreth et al. 
2006).  
Irritable bowel syndrome is one of the most common functional gastrointestinal disorders in 
humans (Cremonini and Talley 2005). It is characterised by abdominal pain and discomfort in 
association with altered bowel habits, whereby symptoms cannot be explained by any 
structural abnormalities (Drossman et al. 2002). Patients suffering from IBS can be classified 
based on the predominating stool pattern into symptom subgroups as diarrhea-predominant 
IBS, constipation-predominant IBS or IBS with alternating bowel movements (mixed IBS) 
(Longstreth et al. 2006). 
Current evidence suggests a number of possible pathogenetical mechanisms including altered 
gastrointestinal motility, visceral hyperalgesia, post-inflammation alterations as well as 
psychosocial and environmental factors amongst others (Camilleri and Andresen 2009). 
Recent studies have focused on inflammatory processes as a key role in the pathophysiology 
of IBS. IBS patients show an increased number of T lymphocytes in intestinal tissue (Spiller et 
al. 2000), increased levels of pro-inflammatory cytokines such as TNFα, IL-8, IL-1β, IL-12 and 
IL-6 and lowered levels of anti-inflammatory cytokines including IL-10 (Bashashati et al. 2012). 
Gene polymorphism within the pro-inflammatory TNFα and anti-inflammatory IL-10 gene has 
been discussed as a risk factor for an altered immunological function in patients with IBS 
(Barkhordari et al. 2010). Furthermore, acute enteric infection has been shown to be an 
important risk factor for the development of IBS. So called post-infectious IBS (PI-IBS) occurs 
after an initial episode of acute gastrointestinal infection (Spiller and Campbell 2006). Patients 
with PI-IBS show a residual inflammation that gradually decreases, and persists for a year and 
longer (Scalera and Loguercio 2012). 
In vivo studies indicated, that pain hypersensitivity and an enhanced colonic motility – 
characterised by increased phasic motility and enhanced smooth muscle tone – are 
independent factors contributing to symptom severity of IBS patients (Kanazawa et al. 2008). 
Intestinal hypermotility, amongst others, is therefore one target to control abdominal pain and 
diarrhea in IBS therapy which can be addressed by the use of antispasmodic and muscle 
relaxing agents. 
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However, traditional IBS therapies are mainly intended for the relief of individual symptoms 
and of limited efficacy in addressing the overall symptom complex (Camilleri and Andresen 
2009). 
In this context, the use of herbal medicinal products is a promising strategy in targeting the 
multifactorial pathophysiology of IBS, as they often provide a multi-target approach and a 
comparably low incidence for adverse events (Efferth and Koch 2011; Wagner 2006). 
1.2 The herbal medicinal product Myrrhinil-Intest®  
Myrrhinil-Intest® is the trade-mark name of a fixed combination consisting of myrrh, chamomile 
flower and coffee charcoal. It entered the market in Germany in 1959. Following the 
introduction of a national legal framework for medicines with the establishment of the German 
Medicines Act in 1976 (effective from 1st January 1978), it obtained a so-called subsequent 
approval by the Commission E in 2001. This subsequent approval was granted for medicines 
with in principle well-known constituents for which safety and efficacy was demonstrated by a 
scientific advisory board (German Commission E), whereby the manufacturer had to provide 
evidence for quality only. After the implementation of an European regulatory framework for 
herbal medicinal products in 2004 with the ‘Directive on Traditional Herbal Medicinal Products’ 
(Directive 2004/24/EC), which allows registration as a “traditional herbal medicinal product”, 
the regulatory status of Myrrhinil-Intest® had to be adapted to a traditional use registration in 
2008. 
Myrrhinil-Intest® is indicated for the relief of gastrointestinal symptoms associated with 
functional gastrointestinal disorders. Its therapeutic use is mainly based on empiric knowledge 
by health care practitioners and focuses on the relief of symptoms associated with 
gastrointestinal disorders. The indication area is not clearly defined but several case reports 
and observational studies reflect the range of therapeutic indications and demonstrate clinical 
effectiveness.  
In a study performed by Gruia for the treatment of gastroenteritis, gastroenteritis associated 
with diarrhea and enterocolitis, symptom relieve was observed after four weeks treatment with 
Myrrhinil-Intest® in the majority of patients (Gruia 1987). Beckmann et al. reported antimycotic 
effects in vitro which were confirmed in an in vivo case study by Lühr for the treatment of 
intestinal mycosis (Beckmann et al. 1996; Lühr 1996). A case report by Schinke suggests the 
use of Myrrhinil-Intest® in combination with products for intestinal sanitation for the treatment 
of chronic diarrhea (Schinke 2011). Stange et al. reported about a favourable development of 
a colitis ulcerosa case after Myrrhinil-Intest® administration as concomitant medication (Stange 
et al. 2004). Furthermore, Langhorst et al. performed a clinical trial over a 12 months period 
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for maintaining remission in ulcerative colitis. In this double-blind, double-dummy study, non-
inferiority was found for the treatment with Myrrhinil-Intest® against mesalazine (Langhorst et 
al. 2013). 
It becomes apparent from the clinical reports that the therapeutic area for which Myrrhinil-
Intest® is applied, covers various gastrointestinal disorders such as intestinal mycosis, chronic 
diarrhea and inflammatory bowel disease as well as irritable bowel syndrome. 
1.2.1 Myrrh, Commiphora molmol 
Myrrh is described as the oleo-gum resin from mainly Commiphora molmol Engler 
(Burseraceae). The resin is obtained by incision or produced by spontaneous exudation from 
stem and branches of Commiphora species (Myrrha. European pharmacopoeia 2008). The 
reddish-brown resinous exudate has a bitter and acrid taste and a balsamic odour (Evans and 
Trease 1989). 
Myrrh consists mainly of volatile oil (3-8 %), alcohol-soluble resin (25-40 %) and water-soluble 
gum (30-60 %) (Tucker 1986). The main constituents of the volatile oil are furano-
sesquiterpenes, while the resin is comprised of di- and triterpenes. The water-soluble gum 
fraction consists of a heterodispers mixture of proteoglycans (Hanus et al. 2005; Wiendl et al. 
1995).  
The medicinal usage of myrrh dates back to biblical times and has been mentioned in both the 
Bible and the Koran as well as in ancient literature of Rome and Greece (Madaus 1938). Its 
traditional uses cover treatment of wounds, pain, arthritis, fractures, obesity, parasitic infection 
and gastrointestinal disorders (Shen et al. 2012). The German Commission E recommends 
the external use of myrrh for topical treatment of mild inflammations of the oral and pharyngeal 
mucosa, because of its adstringent properties (Bundesinstitut für Arzneimittel 15.10.1987). 
1.2.2 Chamomile, Matricaria recutita  
Chamomile flowers are the dried flower heads of Matricaria recutita L. (Asteraceae) indigenous 
to the Eastern Mediterranean region. The flowers have a pleasant sweet-herbaceous and fruity 
odour and an aromatic, slightly bitter taste (Hänsel and Sticher 2010). Main constituents of 
chamomile flowers are essential oil (0.4 – 2.0 %) composed of chamazulene and α-bisabolol, 
amongst flavonoids (up to 8 %) with mainly apigenin, quercetin and luteolin. Other constituents 
include polysaccharides, lipids and coumarins (Maha Aboul Ela 2012) 
Chamomile has been used for centuries as a medicinal plant because of its well-known anti-
inflammatory, antioxidant and mild adstringent properties (Gupta 2010; Weiss and Fintelmann 
2000).  
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The anti-inflammatory potential of chamomile flowers is well known and has been confirmed 
in several animal models such as the carrageenan-induced rat paw oedema model (Al-Hindawi 
et al. 1989; Gerritsen et al. 1995) or the croton oil induced oedema model (Della Loggia et al. 
1990; Tubaro et al. 1984). Furthermore, beneficiary effects of chamomile-containing rinses for 
the treatment of oral mucositis or stomatitis induced by cancer therapies as well as the topical 
treatment on inflammations of the skin was demonstrated in several clinical studies (Aertgeerts 
et al. 1985; Carl and Emrich 1991; Fidler et al. 1996; Patzelt-Wenczler and Ponce-Pöschl 
2000). 
The spasmolytic activity of chamomile flowers has been investigated in several animal models. 
Antispasmodic effects of the chamomile component (-)-α-bisabolol have been reported by 
Hava and Janku already in 1957. Forster et al. further demonstrated the inhibitory activity of 
an ethanolic chamomile extract (31 % v/v ethanol, DER: 1:3.5) on acetylcholine- and 
histamine-induced contractions in isolated guinea pig ileum (Forster et al. 1980). Furthermore, 
Achterrath-Tuckermann et al. found that especially α-bisabolol and to a fewer extent the 
bisabololoxides A and B are responsible for the spasmolytic activity (Achterrath-Tuckermann 
et al. 1980). A positive monograph of the German Commission E recommends the internal use 
of chamomile flowers as oral infusion for the treatment of gastrointestinal spasms and 
inflammatory diseases of the gastrointestinal tract. External use as rinses or bath additive is 
recommended for the treatment of skin and mucous membrane inflammations (Bundesinstitut 
für Arzneimittel 05.12.1984). 
1.2.3 Coffee charcoal, Coffea Arabica 
Coffee charcoal is described as the milled, roasted to blackening outer seed parts of green 
dried Coffea Arabica L. fruits (Rubiaceae). August G. Heisler introduced coffee charcoal into 
medical practice around 1937 for the treatment of various diseases such as angina, scarlet 
fever, parodontosis but also acute and chronic gastrointestinal disorders. The term coffee 
charcoal might be misleading as it must not be understood as a carbonised product such as 
activated charcoal (carbo medicinalis), but overroasted coffee, which retains its aroma and 
most of its constituents (Kuhn and Schäfer 1939). 
The main constituents of the unroasted beans (green coffee) are purine alkaloids with mainly 
caffeine, the nicotinic acid derivative trigonelline, acids and esters including chlorogenic acids 
and aliphatic acids, lipids including coffee oil and diterpenes (Clarke 2003; Trugo 2003). The 
seed composition changes during the roast process due to pyrolysis, caramelisation and 
Maillard reactions. The lipid fraction is relatively heat stable and also the caffeine content is 
not markedly altered during roasting. However, chlorogenic acids undergo many changes and 
due to thermal instability degradation occurs upon drastic roasting conditions (Farah and 
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Donangelo 2006). Roasting furthermore degrades trigonelline, producing a variety of 
compounds including nicotinic acid and volatile compounds such as pyrrols, pyridines and 
methyl nicotinate (Trugo 2003).  
The main constituents of coffee charcoal are similar to those of roasted coffee, however the 
quantities differ due to the longer roasting time. Kuhn and Schäfer have analysed the 
ingredients of coffee charcoal and found that the content of caffeine and chlorogenic- and 
caffeic acid is not markedly reduced and coffee charcoal contains 75 % of the caffeine content 
in roasted coffee. However, it contains only half of the trigonelline content of roasted coffee 
(Kuhn and Schäfer 1939). 
Coffee charcoal is marketed in Germany since many decades under the trade name “Carbo 
Königsfeld®” also known as “Heislersche Kaffeekohle” for the treatment of unspecific acute 
diarrhea. The medicinal use of coffee charcoal (coffea carbo) is recommended by the German 
Commission E for the treatment of unspecific, acute diarrhea and local therapy of mild 
inflammation of the oral pharyngeal mucosa because of its absorbent and adstringent 
properties (Bundesinstitut für Arzneimittel 05.05.1988). 
1.3 Motivation and thesis objective 
Following the establishment of the German Medicines Act in 1976, which introduced a 
definition of medicinal products, manufacturers were obliged to provide proof of quality for the 
medicinal product, whereby safety and efficacy for in principle well-known constituents of 
herbal medicinal products could be demonstrated by the Commission E. Myrrhinil-Intest® 
obtained a subsequent approval within this regulatory context in 2001. 
In the course of further harmonisation across the European Union the Directive on Traditional 
Herbal Medicinal Products (Directive 2004/24/EC) introduced a regulatory framework for 
herbal medicinal products which allows a registration as “traditional herbal medicinal product” 
or marketing authorisation for well-established medicinal products. Within this context, the 
regulatory status for Myrrhinil-Intest® had to be adapted to a traditional use registration and 
new documentation in line with the requirements from the directive (Directive 2004/24/EC 
§ 16a) has to be provided. One aspect within these requirements concerning pharmacological 
proof, asks for "plausibility of pharmacological effects or efficacy of the medicinal product on 
the basis of long-standing use and experience" (Directive 2004/24/EC § 16a). 
Alongside with these increasing regulatory requirements for herbal medicinal products, 
companies were obliged to provide, inter alia, solid data regarding efficacy of their medicinal 
product. This knowledge has to be reinforced with the provision of robust preclinical data. 
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Therefore, detailed information about molecular and functional effects in vitro as well as in vivo 
are required to elucidate underlying mechanisms, which could contribute to the plausibility of 
clinical effectiveness. To address the increasing need for robust preclinical data, the 
pharmacological profile of Myrrhinil-Intest® has to be updated with the means of modern 
biochemical and pharmacological methods. 
Looking at the spectrum of therapeutic indications which have emerged during the past 
50 years, mainly spasmolytic and anti-inflammatory effects seem to contribute to the reported 
therapeutic effectiveness.  
For the treatment of inflammatory intestinal disorders such as inflammatory bowel disease and 
irritable bowel syndrome, intestinal hypermotility is a promising target to control abdominal pain 
and diarrhea. In this context, spasmolytic activities besides anti-inflammatory effects are of 
interest to target inflammation-induced contractile disturbances. 
Especially the anti-inflammatory and spasmolytic effects of chamomile are well-established and 
known for centuries. It is however necessary to obtain a complete picture of the pharmacological 
profile of the specific plant preparations used in Myrrhinil-Intest®. 
In this context the objective of the investigations were to elucidate the following questions: 
Are pharmacological effects such as spasmolytic and anti-inflammatory activities of the 
single components of Myrrhinil-Intest® (myrrh, chamomile flower and coffee charcoal) 
detectable, which provide a rational for the treatment of inflammatory intestinal disorders? 
What mechanisms could be underlying the pharmacological activities? 
In order to examine these issues, the aims of the present thesis were in particular:  
i. Investigation of spasmolytic activities of the myrrh, chamomile and coffee charcoal 
preparations. These should be examined using isometric tension measurement of 
isolated rat small intestinal preparations. Furthermore, spasmolytic activities should be 
revised under inflammatory conditions since gastrointestinal disorders are often 
accompanied by inflammatory processes and alterations in morphology and motility of 
intestinal tissue have been reported (Poli et al. 2001). 
ii. Investigation of anti-inflammatory activities of the myrrh, chamomile and coffee 
charcoal preparations. For the examination an in vitro model for acute inflammation of 
rat small intestinal preparations should be used. Estimation of the inflammatory 
damage should be based on functional performance using isometric tension 
measurement, morphology using histological analysis and expression of TNFα-mRNA 
using quantitative PCR. 
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iii. Investigation of anti-inflammatory activities of the myrrh, chamomile and coffee 
charcoal preparations using cell culture methods. In particular it should be examined, 
whether the components influence cytokine signalling of immune cells. 
iv. Determination of mechanisms underlying potential anti-inflammatory activities of the 
components, using gene expression analysis in native human macrophages. 
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2 Material and methods 
2.1 Preparation of plant material 
The herbal medicinal product Myrrhinil-Intest® is a combination product consisting of 
chamomile flower extract, powdered myrrh and powdered coffee charcoal. For 
pharmacological testing, suitable formulations needed to be established out of the original 
plant material which was used for the manufacturing process. Therefore, aqueous and/or 
ethanolic extracts were produced if necessary. 
2.1.1 Powdered myrrh 
Powdered myrrh as source material, compliant with specifications in the European 
Pharmacopoeia monograph (Myrrha. European pharmacopoeia 2008), was provided by 
Lomapharm, Emmerthal, Germany (Myrrhe Gum EB/BP pulv., batch-no. JA0167, Lomapharm, 
Emmerthal, Germany). For the pharmacological testing, an aqueous and an ethanolic extract 
was prepared. Figure 1 shows a schematic outline of the extraction processes. 
For the preparation of the aqueous myrrh extract (MYA), 1.0 g powdered myrrh was extracted 
three times with ethanol (30 ml; 96 % v/v) for 30 minutes. The residue was then extracted 
exhaustively with purified water (first extraction: 40 ml purified water for 15 min; second and 
third extraction: 15 ml purified water for 10 minutes). The residue was removed and the 
combined supernatants were freeze dried. The lyophilisate was stored at -20°C until further 
use. 
An ethanolic myrrh extract (MY) was kindly provided by D&S Pharma GmbH (batch-no. 18719, 
01/2012, Ibbenbüren, Germany). For preparation of the dried extract, powdered myrrh was 
extracted under reflux with ethanol (96 % v/v) at 90°C for 60 minutes. After evaporation to 
dryness the residue was suspended in water and steam distillation was performed. The dried 
residue was stored at -20°C until further use. 
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Figure 1: Schematic outline of the extraction process of powdered myrrh. 
For the preparation of the aqueous myrrh extract (MYA), the powdered substance was extracted with 
ethanol followed by an exhaustive water extraction and lyophilisation process. The ethanolic myrrh 
(MY) extract was obtained by ethanolic extraction and subsequent water steam distillation. 
Characterisation of the ethanolic myrrh extract HPLC analysis was performed by D&S Pharma 
GmbH (Ibbenbüren, Germany) using a Multosper 100 RP 18 column (250 mm x 4 mm; 5 μm) 
and a DAD detector (5 cm). The mobile phase consisted of 39 % (v/v) acetonitrile, 60 % (v/v) 
water and 1 % (v/v) acetic acid (I) and 99 % (v/v) water and 1 % (v/v) acetic acid (II) at a flow 
rate of 1.0 ml/min. A gradient program was used as follows: 0 min, 100 % (I); 30 min, 100 % 
(I); 70 min, 90 % (I) and 10 % (II); 80 min, 100 % (I). The monitor wave length of the DAD 
detector was 240 nm. The HPLC fingerprint of ethanolic myrrh extract is presented in Figure 
2. 
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Figure 2: HPLC-fingerprint of the ethanolic myrrh extract (MY). 
HPLC analysis was performed using a Multosper 100 RP 18 column (250 mm x 4 mm; 5 μm) and a 
DAD detector (5 cm) with a mobile phase consisting of 39 % (v/v) acetonitrile, 60 % (v/v) water and 
1 % (v/v) acetic acid (I) and 99 % (v/v) water and 1 % (v/v) acetic acid (II) at a flow rate of 1.0 ml/min. 
Kindly provided by D&S Pharma GmbH, Ibbenbüren, Germany. 
2.1.2 Chamomile flower extract 
The chamomile flower dry extract (EtOH 60 % m/m; DER: 4-6:1; batch-no. HC0070) used in 
the finished dosage form was provided by Lomapharm, Emmerthal, Germany. 
2.1.3 Coffee charcoal 
Powdered coffee charcoal was provided by Lomapharm (Carbo Coffea EB 6, batch-no. 
JB0142, Lomapharm, Emmerthal, Germany). For the preparation of an aqueous extract, 20.0 g 
powdered substance were extracted in 150 ml boiling purified water for 15 minutes. After 
filtration the filtrate was freeze dried and the lyophilisate was stored at -20°C until further use. 
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2.1.4 Determination of endotoxin contamination 
All plant extracts were tested for endotoxin contamination since especially cell biological 
experiments using immune cells react very sensitive to traces of endotoxins which could distort 
the results. Therefore, the ToxinSensor Gel Clot Endotoxin Assay Kit (GenScript, NJ, USA) 
was used according to manufacturer’s instructions. This Limulus Amebocyte Lysate (LAL) test 
is based on the endotoxin-induced coagulation of enzymes in blood cells (amebocytes) of the 
horseshoe crab (Limulus polyphemus) (Levin and Bang 1964). In this study a gel clotting assay 
was preferred instead of a colorimetric assay, since the self-coloration of the extracts could 
distort the interpretation of the results. The test was performed by mixing 100 µl of the 
reconstituted lyophilised Limulus Amebocyte Lysate with 100 µl extract dilutions (1.25 – 
5 x 10-6 g/ml). E.coli endotoxin standard and endotoxin-free water (both provided in kit) were 
used as positive and negative control respectively. After 60 minutes incubation at 37°C the 
samples were analysed visually for gel clotting. 
The test results for all plant extracts were negative in the concentrations tested, which means 
that the endotoxin level in all extracts is below the detection limit of 0.25 endotoxin units 
(EU)/ml corresponding to 25 pg/ml. 
2.1.5 Materials and equipment 
Table 1: Preparation of plant materials – Substances and consumables 
Substance/consumable Supplier 
Myrrhe Gum pulv., (batch-no. JA0167) Lomapharm, Emmerthal, Germany 
Chamomile flower dry extract (EtOH 
60 % m/m; DER: 4-6:1; batch-no. HC0070) 
Lomapharm, Emmerthal, Germany 
Carbo Coffea EB 6 (batch-no. JB0142) Lomapharm, Emmerthal, Germany 
Ethanol, absolute Grüssing GmbH, Filsum, Germany 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Steinheim, Germany 
ToxinSensor Gel Clot Endotoxin Assay Kit GenScript, NJ, USA 
Table 2: Preparation of plant materials – Equipment 
Equipment Manufacturer 
Lyophilisator Christ, Osterode, Germany 
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2.2 Animals and tissue preparation  
Adult male and female Wistar rats (Rattus norvegicus, var. albinos; 12-17 weeks old, 250 to 
500 g body weight) were purchased from Biomedical Centre, Medical Faculty, University of 
Leipzig, Germany. The animals were housed in cages of five at room temperature in a 12 hour 
light/dark cycle. Tap water and standard food pellets were available ad libitum. All experiments 
were performed according to the German Animal Welfare Act and approved by the Institutional 
Review Board of Animal Care Committee (reference number: T 06/13, date of approval: 
12th November 2012). 
Isolation of the ileum/jejunum preparations was performed after the rats were anaesthetised 
with CO2 and sacrificed by decapitation. Subsequently, the abdomen was opened immediately 
by midline incision and the distal segment of the small intestine of approximately 15 cm was 
excised and stored in aerated modified Krebs solution at 37°C.  
2.3 Induction of inflammation – TNBS-inflammation model 
Inflammation was induced by instillation of 2,4,6-trinitrobenzenesulfonic acid (TNBS) into the 
lumen of the ileum/jejunum preparations (TNBS-inflammation model acc. to Warstat 2004). 
Thus, an approximately 2.5 cm long ileum/jejunum preparation was prepared and cleaned. 
One end was closed by a thread whereas a cannula was installed in the other end through 
which TNBS (10-100 mM) or modified Krebs solution was applied (Figure 3). After application, 
the cannula was removed and the end was closed by a thread. Depending on the respective 
objective, the preparations were then treated accordingly: 
For measurement of isometric contractions (see 2.4) the preparations were incubated with 
TNBS (10 mM) or the plant extracts in different concentrations together with TNBS (10 mM) 
for 30 minutes. 
For histological analysis (see 2.5), the preparations were incubated with TNBS (100 mM) or 
the plant extracts in different concentrations together with TNBS (100 mM) for 30 minutes.  
For determination of TNFα gene expression (see 2.6) the preparations were incubated with 
TNBS (10 mM) or the plant extracts in different concentrations together with TNBS (10 mM) 
for 3 hours. 
In all experiments, preparations incubated with TNBS or untreated preparations served as 
positive and untreated controls respectively. 
The incubations were carried out in a 10 ml incubation chamber containing aerated (95 % O2, 
5 % CO2) modified Krebs solution. At the end of incubation time, the threads were removed 
and the preparations rinsed with modified Krebs solution. Sections of 1.5 cm (measurement of 
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isometric contractions) or 0.5 cm (histological analysis and TNFα gene expression analysis) 
length were prepared for the experiments. 
 
Figure 3: Induction of inflammation 
For induction of inflammation a rat ileum/jejunum preparation (2.5 cm) was cleaned and 
2,4,6-trinitrobenzenesulfonic acid (TNBS, 10 mM) was applied through a cannula and incubated for 
30 minutes. 
2.4 Measurement of isometric contractions 
Isometric contraction were measured using an organ bath equipment (TSE Systems, Bad 
Homburg, Germany). The equipment consists of 4 separate organ baths. 
The ileum/jejunum preparations were obtained and treated as outlined in ‘2.2 Animals and 
tissue preparation’ and ‘2.3 Induction of inflammation – TNBS-inflammation model’ and 
suspended in 20 ml organ baths containing aerated (95 % O2, 5 % CO2) modified Krebs 
solution maintained at 37°C. 
Using polyester threads, one end was anchored to a stationary hook at the bottom and 
attached to an isometric transducer (TSE Systems, Bad Homburg, Germany) for continuous 
recording of the isometric tension. The preparations were allowed to equilibrate for 40 minutes 
with a preloaded tension of 10 mN.  
Acetylcholine (ACh, 1 mM) was applied directly into the organ baths to induce tonic contraction. 
After reaching the force maximum the organ baths were rinsed three times with modified Krebs 
solution to remove all applied substances from tissue and bath vessels. 
2.4.1 Test execution 
Depending on the issue in question, different experimental designs were carried out.  
In order to examine the influence on ACh-induced contraction, the following experiment set up 
was used:  
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Figure 4: Experimental set up for investigation of influence on ACh-induced contraction. 
C – Control application of ACh (internal standard); T – Application of test substance two minutes prior 
to ACh application; x – wash out. 
An initial ACh (1 mM) application at minute 20 was performed for conditioning and to test the 
sensitivity of the preparations used. Further single ACh applications (minute: 40, 100 and 160) 
were used as internal standards. Between these control applications, the influence of test 
substances was examined by application two minutes prior to ACh application (minute: 60, 80, 
120 and 140). 
To assess the influence on TNBS-induced contractility decrease, the following experimental 
set up was used: 
 
Figure 5: Experimental set up for investigation of influence on TNBS-induced contractility 
decrease. 
C – Control application of ACh (internal standard); T – Application of ACh; x – wash out. 
After the initial ACh (1 mM) application at minute 20, ACh (1 mM) applications and subsequent 
wash out period were carried out every 20 minutes. 
For the characterisation of calcium antagonistic effects, the following experiment set up was 
applied: 
 
Figure 6: Experimental set up for the characterisation of calcium antagonistic effects.  
C – Control application of ACh; T – Application of test substance; A – Application of calcium channel 
agonist Bay K8644; x – wash out. 
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An initial ACh (1 mM) application at minute 20 was performed to test sensitivity of the 
preparations used. Afterwards, the preparations were pre-treated with the test substance at 
minute 30. Cumulative applications of L-type calcium channel agonist BAY K8644 (10-10 – 
10-5 M) were subsequently conducted every 5 minutes. 
2.4.2 Data analysis 
For data acquisition, BioSys software (TSE Systems, Bad Homburg) was used recording ten 
measured values (force in mN) per second. Further data analysis was performed using 
Microsoft Excel (version 14.0, Microsoft cooperation, Redmond, WA, USA) and Graph Pad 
Prism (version 6.00, GraphPad Software Inc., San Diego, CA, USA) for statistical analysis.  
ACh-induced contractions were expressed as % of the contraction peak induced by a control 
application (minute 40). Basal muscular tone was expressed as mean tension over a 
60 second time period compared to an initial control period (= 100 %). Data are expressed as 
mean ± SEM; n represents the number of different animals used.  
Statistical analysis of ACh-induced contraction was performed by one-way analysis of variance 
(ANOVA) followed by Tukey Multiple Comparison Test. For the characterisation of calcium 
antagonistic effects, concentration-response curves and corresponding parameters such as 
EC/IC50 and Emax were obtained using non-linear regression by GraphPad Prism software. 
Comparison of the parameters EC50 and Emax of the agonistic concentration-response 
curves was done by comparison of fits. Comparison of EC50 values was performed using 
paired, two-tailed t-test. 
Schild analysis for the calculation of pA2 and pD2 values was performed according to the 
following equations:  
  
𝐼:                 𝑝𝐴2 = − log [𝐵] + log
𝐸𝐶50𝐴
𝐸𝐶50𝐴𝐵
− 1 
 
𝐼𝐼:                 𝑝𝐷2 = − log [𝐵] + log
𝐸𝐴
𝐸𝐴𝐵
− 1 
 
 
 
 
[B]  – antagonist concentration 
EC50A  – EC50 value, agonist only 
EC50AB  – EC50 value, after pre-treatment with antagonist;  
EA  – maximum effect, agonist only 
EAB  – maximum effect, after pre-treatment with antagonist 
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2.4.3 Materials and equipment 
Table 3: Isometric tension measurement – Substances and consumables 
Substance/consumable Supplier 
Bay K8644 Sigma-Aldrich, Steinheim, Germany 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Steinheim, Germany 
Acetylcholine (ACh) Sigma-Aldrich, Steinheim, Germany 
2,4,6-Trinitrobenzenesulfonic acid (TNBS) Sigma-Aldrich, Steinheim, Germany 
CO2 Air Liquide, Leipzig, Germany 
Carbogen (95 % O2, 5 % CO2) Air Liquide, Leipzig, Germany 
Table 4: Isometric tension measurement – Substances and consumables (Modified Krebs solution 
acc. to Martinsson) 
Substance/consumable Concentration Supplier 
Modified Krebs solution acc. to Martinsson, pH 7.4 
Sodium chloride (NaCl)  118 mM  
AppliChem, Darmstadt, 
Germany  
Sodium bicarbonate (NaHCO3) 25 mM  
Sigma-Aldrich, Steinheim, 
Germany  
Potassium chloride (KCl) 4,8 mM  
Sigma-Aldrich, Steinheim, 
Germany  
Magnesium sulfate heptahydrate  
(MgSO4 * 7H2O)  
1,2 mM  Fluka, Buchs, Schweiz  
Monopotassium phosphate 
(KH2PO4) 
1,2 mM  Fluka, Buchs, Schweiz  
Calcium chloride dihydrate (CaCl2 * 
2 H2O) 
2,5 mM  
Sigma-Aldrich, Steinheim, 
Germany  
Glucose  11 mM  
Sigma-Aldrich, Steinheim, 
Germany 
Table 5: Isometric tension measurement – Equipment 
Equipment Manufacturer 
Organ bath equipment TSE Systems, Bad Homburg, Germany  
Hand lever guillotine 
Hugo Sachs, March-Hugstetten, 
Germany 
Material and methods   17 
 
 
2.5 Histological analysis 
2.5.1 Fixation, processing, embedding and sectioning of samples for histological 
analysis 
For histological analysis, ileum preparation were prepared and processed as outlined in ‘2.2 
Animals and tissue preparation’ and ‘2.3 Induction of inflammation – TNBS-inflammation 
model’. Morphological variance was kept at a minimum by using particularly the ileum segment 
of the small intestine (4-5 cm). 
After incubation, the preparations were fixated for at least 24 hours in formalin (4 % 
formaldehyde in phosphate buffered saline; pH 7.4) at room temperature and rinsed with 
phosphate buffered saline (PBS, pH 7.4) followed by an initial 60 minute dehydration process 
with 50 and 70 % ethanol (v/v). The fixated preparations were subsequently dehydrated and 
infiltrated with paraffin wax using an automated tissue processor (Leica ASP200S; Leica 
Microsystems; Wetzlar Germany). A schematic representation of the embedding process is 
shown in Figure 7.  
 
Figure 7: Schematic embedding process 
After dehydration with increasing ethanol concentrations and xylol treatment preparations were 
infiltrated and stored in paraffin (59°C).  
2.5.2 Preparation and staining of paraffin sections 
After paraffin infiltration, the preparations were stored in liquid paraffin at 59°C and embedded 
in paraffin blocks using an embedding machine (Leica EG1160 Leica Microsystems, Wetzlar, 
Germany). After cooling and hardening of the paraffin blocks, a rotary microtome (Leica 
RM2255, Leica Microsystems, Wetzlar Germany) was used to prepare slices of 7 µm layer 
thickness which were placed on a microscope slide. 
2.5.3 Hematoxylin and eosin (HE) staining 
Hematoxylin and eosin (HE) staining is a routine staining method to visualise tissue 
morphology. The process uses a haematoxylin dye to stain basophilic structures like cell nuclei 
blue and an eosin dye to stain acidophilic structures like cytoplasm and cell walls pink or red.  
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Before staining, the slices were deparaffinised using xylol and ethanol (99.8 – 70 % v/v). After 
rehydration, staining with hematoxylin (Hematoxylin-solution, Mayer’s, Dr. K. Hollborn & Söhne 
GmbH & Co KG, Leipzig, Germany) and eosin solution (0.1 %) was performed followed by a 
dehydration process using ethanol (99.8 % v/v) and xylol. The complete staining procedure is 
presented in Figure 8. For the preparation of durable samples slides were mounted with 
Canada Balsam (Dr. K. Holborn, Leipzig, Germany). 
 
Figure 8: HE-staining protocol 
After rehydration using xylol and decreasing ethanol concentrations, preparations were stained with 
hematoxylin and eosin followed by a dehydration process using ethanol and xylol. 
2.5.4 Data analysis 
After hardening of the mounting medium, morphometric analysis was performed using a 
transmitted-light microscope (Leica DMRBE, Leica Wetzlar Germany). Mucosa layer thickness 
was determined using ImageJ software (version 1.47 Wayne Rashband, National Institute of 
Health, USA) in three replicates within one sample and mean values were evaluated (Figure 
9). Statistical analysis was performed by one-way analysis of variance (ANOVA) followed by 
Tukey Multiple Comparison Test using Graph Pad Prism software (version 6.00, GraphPad 
Software Inc., San Diego, CA, USA). Mucosa layer thickness of untreated preparations served 
as control (100 %). Data are expressed as mean ± SEM; n represents the number of different 
animals used.  
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Figure 9: Morphometric analysis of rat ileum preparations 
Mucosa layer thickness [µm] was measured using ImageJ software (version 1.47 Wayne Rashband, 
National Institute of Health, USA). 
2.5.5 Materials and equipment 
Table 6: Histological analysis - Substances and consumables – formalin 4 %; pH 7.4 
Substance Amount Supplier 
Paraformaldehyde 4.0 g Sigma-Aldrich, Steinheim, Germany 
Monosodium phosphate (NaH2PO4) 0.96 g Sigma-Aldrich, Steinheim, Germany 
Disodium phosphate (Na2HPO4) 0.284 g Sigma-Aldrich, Steinheim, Germany 
Aqua purificata 100 ml  
Table 7: Histological analysis - Substances and consumables – phosphate buffered saline (PBS); 
pH 7.4 acc. to Sørensen 
Substance Amount Supplier 
Monopotassium phosphate 
(KH2PO4) 
2.722 Fluka, Buchs, Schweiz 
Disodium phosphate (Na2HPO4) 11.36 g Sigma-Aldrich, Steinheim, Germany 
Aqua purificata 1000 ml  
Table 8: Histological analysis - Substances and consumables – Eosin solution 
Substance Amount Supplier 
Eosin 0.1 g Sigma-Aldrich, Steinheim, Germany 
Acetic acid 1 gt  
Aqua purificata 100 ml  
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Table 9: Histological analysis - substances and consumables 
Substance Supplier 
Hematoxylin-solution, Mayer’s 
Dr. K. Hollborn & Söhne GmbH & Co KG, 
Leipzig, Germany 
Canada Balsam 
Dr. K. Hollborn & Söhne GmbH & Co KG, 
Leipzig, Germany 
Table 10: Histological analysis - equipment 
Equipment Manufacturer 
Automated tissue processor  
(Leica ASP200S) 
Leica Microsystems, Wetzlar, Germany 
Embedding machine (Leica EG1160) Leica Microsystems, Wetzlar, Germany 
Rotary microtome (Leica RM2255) Leica Microsystems, Wetzlar, Germany 
Transmitted-light microscope  
(Leica DMRBE) 
Leica Microsystems, Wetzlar, Germany 
2.6 TNFα gene expression analysis in ileum/jejunum preparations 
2.6.1 RNA-preparation and reverse transcription 
The ileum/jejunum preparations were obtained and treated as described in 2.2 ‘Animals and 
tissue preparation’ and 2.3 ‘Induction of inflammation – TNBS-inflammation model’. After 
incubation, tissue segments of approximately 0.5 cm length were obtained and total RNA was 
isolated using peqGOLD RNAPure (PEQLAB Ltd., Erlangen, Germany) according to 
manufacturer's instructions. Thus, samples were incubated for five minutes in 1 ml peqGOLD 
RNA Pure (phenol and guanidinium thiocyanate) at room temperature. After incubation 200 µl 
chloroform were added and the mixture was shaken for 15 seconds and placed on ice for 
10 minutes. After phase separation and centrifugation, the aqueous phase including dissolved 
RNA was removed and the same volume of isopropyl alcohol was added. After 15 minutes 
incubation on ice the precipitated RNA was centrifuged and supernatant was removed. After 
two washing steps with ethanol (70 % v/v) the RNA pellet was dissolved in 30 µl nuclease-free 
water. 
For cDNA synthesis oligo(dT)-primed reverse transcriptase was performed using RevertAid 
First Strand cDNA Synthesis Kit (Thermo Fisher Scientific Inc., Waltham, MA, USA) according 
to manufacturer's instructions. Thus, aliquots of 10 µg RNA were mixed with 1 µl Oligo(dT)18 
Primer (Thermo Fisher Scientific Inc., Waltham, MA, USA) and incubated for 5 minutes at 70°C 
(MJMini™ Personal Thermal Cycler) followed by an incubation on ice for 2 minutes. A master 
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mix consisting of the following components was then added to each tube: 4 μl 5x first-strand 
buffer, 1.5 µl nuclease-free water, 0.5 µl RiboLock RNase Inhibitor, 2 µl desoxyribonucleotide 
triphosphate mix (dNTP mix, 10 mM each dATP, dGTP, dCTP, dTTP in DNase/RNase 
ultrapure water) and 1 μl RevertAid H Minus Reverse Transcriptase (Thermo Fisher Scientific 
Inc., Waltham, MA, USA). The mixture was then incubated at 42°C for 60 minutes followed by 
an inactivation step at 70°C for 10 min.  
RNA and cDNA quantity and purity were assessed using NanoDrop 2000/2000c 
spectrophotometer (Thermo Fisher Scientific Inc., Waltham, MA, USA). Nucleic acid purity was 
determined by the ratio of absorbance at 260 nm to 280 nm (approximately 1.8 for DNA; 
approximately 2.0 for RNA) and at 260 and 230 (between 1.8 and 2.2). cDNA samples were 
stored at -20°C until further use. 
2.6.2 Quantitative real-time PCR (qPCR) 
Quantitative determination of TNFα-gene expression was performed by quantitative real-time 
PCR on a MyIQ™ Cycler (Bio-Rad, Munich, Germany) using KAPATM SYBR® FAST, qPCR 
Universal MasterMix (PEQLAB Ltd., Erlangen, Germany) according to manufacturer's 
instructions. The applied reaction set up for 15 µl total reaction volume is specified in Table 
11. All qPCR reactions were run in duplicates and amplified using the amplification program 
specified in Table 12. Melt curve analysis was performed after the last cycle, to monitor the 
assay’s specificity, whereby a single melt curve for each amplicon was required for specificity 
validation. 
As reference gene ‘18S’ ribosomal RNA was utilised as endogenous control for relative 
quantification of the target gene. 
Table 11: qPCR Reaction set up 
Component Volume 
KAPATM SYBR® FAST, qPCR MasterMix (2x) 7.5 µl 
Forward Primer (5 µM) 1.5 
Reverse Primer (5 µM) 1.5 
cDNA template 1 µl 
Water, nuclease-free 3.5 
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Table 12: qPCR amplification program and melt curve analysis 
Step Temperature Duration Cycles 
KAPATM SYBR® DNA polymerase activation 95°C 10 min 1 x 
Denaturation 95°C 15 sec 
40 x Annealing 60°C 30 sec 
Elongation 72°C 30 sec 
Dissociation 95°C 6 min 1 x 
Melt curve analysis 55 - 95°C 10 sec  
80 x 
(Δ0.5°C) 
2.6.3 Data analysis 
For the quantitative comparison of amplification rates of TNFα, the ΔΔCt method was used. 
The threshold cycle (Ct value) defines the fluorescence signal point where a background 
fluorescence is exceeded. For normalisation, the Ct value of the reference gene 18S was 
subtracted from the Ct value of the target gene (= ΔCt value). Relative gene expression of the 
target gene was then determined in relation to the untreated control (ΔΔCt) and is represented 
as ‘-fold change’. 
Statistical analysis was performed by one-way analysis of variance (ANOVA) followed by 
Tukey Multiple Comparison Test using Graph Pad Prism (version 6.00, GraphPad Software 
Inc., San Diego, CA, USA. Data are expressed as mean ± SEM; n represents the number of 
different animals used.  
2.6.4 Materials and equipment 
Table 13: Specification of primers used for qPCR 
 Sequence Source 
Rattus norvegicus 18S ribosomal RNA   
sense 5’-ACGATGCCGACTGGCGATGC-3‘ Hoser et al. 2011 
antisense 5’-GCTCCACCAACTAAGAACGGCCA-3‘ Hoser et al. 2011 
Rattus norvegicus tumor necrosis factor, mRNA 
sense 5’-TCAGCCTCTTCTCATTCCTG-3’ Michael et al. 2010 
antisense 5’-GGCTACGGGCTTGTCACTCG-3’ Michael et al. 2010 
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Table 14: TNFα gene expression in ileum/jejunum preparations - Substances and consumables 
Substance/consumable Supplier 
peqGOLD RNAPure  PEQLAB, Erlangen, Germany  
water (nuclease-free) 
Thermo Fisher Scientific Inc., Waltham, 
MA, USA 
Oligo(dT)18 Primer 
Thermo Fisher Scientific Inc., Waltham, 
MA, USA 
dNTP Mix 
Thermo Fisher Scientific Inc., Waltham, 
MA, USA 
5x Reaction Buffer 
Thermo Fisher Scientific Inc., Waltham, 
MA, USA 
RiboLock™ RNase-Inhibitor  
Thermo Fisher Scientific Inc., Waltham, 
MA, USA 
RevertAid™ H Minus Reverse 
Transcriptase  
Thermo Fisher Scientific Inc., Waltham, 
MA, USA 
Reaction tubes (0.2, 0.5, 1.5 ml)  Sarstedt, Nürnbrecht, Germany  
Transperent PCR foil, self-adhesive, 
DNase/RNase-free 
Sarstedt, Nürnbrecht, Germany  
96 well PCR-plates, DNase/RNase-free PEQLAB, Erlangen, Germany  
Table 15: TNFα gene expression in ileum/jejunum preparations - Equipment 
Equipment Manufacturer 
Centrifuge ‘Biofuge Pico‘ Heraeus, Osterode, Germany  
Spectrophotometer Ultrospec 2000  Pharmacia Biotech, Dübendorf, Germany  
MJMini™ Personal Thermal Cycler  Bio-Rad, Munich, Germany  
Plate centrifuge ‘Allegra’ Beckman Coulter, Krefeld, Germany  
Realtime RT-PCR MyIQ™ Cycler  Bio-Rad, Munich, Germany  
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2.7 Cell culture  
2.7.1 Differentiated THP-1 cells 
THP-1 is a human leukemic cell line, originally derived from the peripheral blood of an 
one-year-old male infant with acute monocytic leukemia, which expresses distinct monocytic 
markers (Tsuchiya et al. 1980). In contrast to native human monocytes, this cell line offers the 
advantage of a homogeneous population, which markedly facilitates biochemical studies. 
Under the influence of phorbol esters such as TPA (12-O-tetradecanoylphorbol-13-acetate) or 
PMA (phorbol-12-myristate-13-acetate), THP-1 cells differentiate into macrophage-like cells 
(Tsuchiya et al. 1982), which are commonly used to model macrophage function. 
Cell culture and differentiation of THP-1 cells 
THP-1 cells (ATCC, TIB-202) in a concentration of 1-10 x 106 were cultured in RPMI 1640 (PAA 
Laboratories GmbH, Pasching, Austria) supplemented with fetal calf serum (FCS, 10 %; PAA 
Laboratories GmbH, Pasching, Austria) and penicillin/streptomycin (P/S, 1 %; Biochrom AG, 
Berlin, Germany) at standard cell culture conditions. 
For the differentiation to macrophage-like cells, phorbol-12-myristate-13-acetate (PMA; 
Sigma-Aldrich, Steinheim, Germany) in a concentration of 100 ng/ml was added to the culture 
medium and cells were allowed to differentiate for 48 hours at 37°C in 5 % CO2 humidified air. 
2.7.2 RAW 264.7 macrophages 
The murine macrophage cell line RAW 264.7, which was established from murine tumours 
induced with Abelson leukemia virus by Raschke et al. in 1978, expresses properties of 
macrophages and serves as a suitable model for macrophage function (Raschke et al. 1978). 
All experiments with this cell line were kindly allowed to be performed at the Institute of 
Pharmaceutical Biology and Phytochemistry, University of Münster, in the laboratories of Prof. 
A. Hensel. In this context only aqueous (0.01 – 1000 µg/ml) and ethanolic myrrh extract (0.001 
– 100 µg/ml) have been tested. 
RAW 264.7 cells (ATCC, TIB-71) in a concentration of 1-10 x 106 were cultured in DMEM (high 
glucose, plus glutamine; PAA Laboratories GmbH, Pasching, Austria) supplemented with fetal 
calf serum (FCS, 10 %; Thermo Scientific, Waltham, USA), penicillin/streptomycin (P/S, 1 %; 
PAA Laboratories GmbH, Pasching, Austria) at standard cell culture conditions. 
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2.8 Determination of TNFα release (TNFα-ELISA) 
2.8.1 LPS stimulation and substance incubation 
After differentiation to macrophage-like cells, THP-1 cells were stimulated with LPS (100 ng/ml, 
Lipopolysaccharide from E. coli 0111:B4; Sigma-Aldrich, Steinheim, Germany) for four hours. 
LPS incubation polarises PMA treated THP-1 cells towards the pro-inflammatory M1-subtype 
and induces a strong pro-inflammatory response as it has been demonstrated before (Chanput 
et al. 2013). 
To determine the influence of the plant extracts on inflammatory response e.g. TNFα release, 
the substances were incubated simultaneously with LPS (100 ng/ml) in their respective 
concentration. Budesonide (1 nM; Sigma-Aldrich, Steinheim, Germany) served as positive 
control. Medium or DMSO in applied concentrations served as vehicle control. For the 
determination of TNFα release, all plant extracts were tested in double determination on 
LPS-stimulated and untreated cells. All samples were incubated at standard cell culture 
conditions (37°C in 5 % CO2 humidified air) for four hours. 
After incubation, the supernatants were removed completely and after one centrifugation step 
the cell-free lysates were stored until further use at -80°C. The supernatants were used for 
determination of TNFα release and cytotoxicity testing (LDH-assay, see 2.10.2). Remaining 
cells on the cell culture plate were used for cell viability test (MTT-assay, see 2.10.1). 
2.8.2 Test execution 
For the determination of TNFα release by enzyme-linked immunosorbent assay (ELISA), the 
human TNF ELISA Kit II BD OptEIA™ (BD Biosciences, Franklin Lakes, NJ, USA) was used 
according to manufacturer’s instructions. 
Thus, after the high binding ELISA plate (96 well) has been coated with the antigen-specific 
capture antibody, the TNFα molecules in the collected supernatants were allowed to bind to 
the capture antibody. In a next step, a biotinylated detection antibody bound to the antigen 
providing a binding site for the enzyme, which catalysed a colour reaction, when the specific 
substrate (hydrogen peroxide and tetramethylbenzidin) was added. The formation of the 
coloured product, which correlates directly with the amount of TNFα in the samples, was 
detected spectrophotometrically at 450 nm with a reference wave length at 570 nm. For 
quantification, a standard curve was established for each experiment using known amounts of 
human TNFα (provided in kit). 
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2.8.3 Data analysis 
Recording of the extinction data was done using ADAP basic software (Anthos Mikrosysteme 
GmbH, Krefeld, Germany).  
Further data analysis was performed using Microsoft Excel (version 14.0, Microsoft 
cooperation, Redmond, WA, USA) and Graph Pad Prism (version 6.00, GraphPad Software 
Inc., San Diego, CA, USA) for statistical analysis. 
TNFα release was expressed as % of the TNFα release induced by untreated or LPS-
stimulated cells respectively. Data are expressed as mean ± SEM; n represents the number of 
independent experiments. 
Statistical analysis was performed by one-way analysis of variance (ANOVA) followed by 
Tukey Multiple Comparison Test. For the determination of concentration effect relations, 
concentration-response curves and corresponding parameters such as EC/IC50 were 
obtained using non-linear regression by GraphPad Prism software. The selectivity index (SI) 
was determined using the IC50 value of cell viability and the IC50 value of TNFα release 
according to the following equation:  
𝑆𝐼 =  
𝐼𝐶50 𝐴
𝐼𝐶50 𝐵
 
SI: selectivity index 
IC50 A: half maximal inhibitory concentration of cell viability (MTT assay) 
IC50 B: half maximal inhibitory concentration of TNFα release 
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2.8.4 Materials and equipment 
Table 16: TNFα release – Substances and consumables 
Substance/consumable Supplier 
RPMI medium 1640 (1x), with glutamine 
PAA Laboratories GmbH, Pasching, 
Austria 
Fetal calf serum (FCS), heat inactivated 
PAA Laboratories GmbH, Pasching, 
Austria 
Penicillin 10.000 units/streptomycin 10 mg Biochrom AG, Berlin, Germany 
Phorbol-12-myristate-13-acetate (PMA) Sigma-Aldrich, Steinheim, Germany 
Lipopolysaccharide from E. coli 055B5 Sigma-Aldrich, Steinheim, Germany 
Budesonide Sigma-Aldrich, Steinheim, Germany 
Cell culture multiwell plates (96-well) 
Techno Plastic Products AG, 
Trasadingen, Schweiz 
ELISA-plates, Microlon, 96 well,  
high binding 
Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Neubauer counting chamber Fein-Optik, Bad Blankenburg, Germany 
Serological pipettes Sarstedt AG & Co., Nümbrecht, Germany 
Cell culture flasks (75 cm²)  Sarstedt AG & Co., Nümbrecht, Germany 
Centrifuge tubes (15 ml, 50 ml)  
Techno Plastic Products AG, 
Trasadingen, Schweiz 
Human TNF ELISA Kit II BD OptEIA™ BD Biosciences, Franklin Lakes, NJ, USA 
Table 17: TNFα release – Equipment 
Equipment Manufacturer 
Laminar Flow Bench Biowizard Kojair® UniEquip, Leipzig, Germany 
Multi-gas incubator  
Sanyo Sales & Marketing Europe GmbH, 
Munich, Germany 
Freezer 
Harris Manufacturing Company, North 
Billerica, M.A. 
UV/VIS-spectrometer Anthos Reader 2010 
Anthos Mikrosysteme GmbH, Krefeld, 
Germany 
Test tube shaker lab dancer 
VWR International GmbH, Darmstadt, 
Germany 
Vortex shaker Reax 2000 
Heidolph Instruments GmbH & Co. KG, 
Schwabach, Germany 
Centrifuge HERMLE Z232K UniEquip, Leipzig, Germany 
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2.9 Determination of nitric oxide release 
2.9.1 LPS stimulation and substance incubation 
To induce an inflammatory response, cells were stimulated with LPS (100 ng/ml, 
Lipopolysaccharide from E. coli 0111:B4; Sigma-Aldrich, Steinheim, Germany) for 24 hours. 
To determine the influence of the plant extracts on the inflammatory response represented by 
nitric oxide (NO) release, the substances were incubated simultaneously with LPS in their 
respective concentration. The inducible nitric oxide synthase inhibitor aminoguanidine 
(100 µg/ml; Caymann Chemical Company, Ann Arbor, USA) served as positive control. 
Medium or DMSO in applied concentrations served as vehicle control. For the determination 
of NO release, all plant extracts were tested in triple determination on LPS-stimulated and 
untreated cells. All samples were incubated at standard cell culture conditions (37°C in 5 % 
CO2 humidified air) for 24 hours. 
After incubation, the supernatants were removed completely and used for determination of NO 
release. Remaining cells on the cell culture plate were used for cell viability test (MTT assay, 
see 2.10.1). 
2.9.2 Test execution 
After LPS stimulation, nitric oxide (NO) production was determined using Griess reagent. In 
aqueous solution, nitric oxide rapidly degrades to nitrate and nitrite. After addition of Griess 
reagent (1% sulfanilamide; 0.1% N-(1-naphthyl)ethylenediamine dihydrochloride; 4.3 % 
phosphoric acid), the resulting nitrite in the samples can be detected spectrophotometrically 
after the induced diazonium coupling reaction.  
Thus, after LPS and substance incubation the collected supernatant was incubated with Griess 
reagent. After an incubation time of 30 minutes, the formation of the azo compound was 
measured spectrophotometrically at 540 nm with a reference wave length at 690 nm. 
2.9.3 Data analysis 
Recording of the extinction data was done using Sunrise microplate reader software (Tecan, 
Grödig, Austria). Further data analysis was performed using Microsoft Excel (version 14.0, 
Microsoft cooperation, Redmond, WA, USA) and Graph Pad Prism (version 6.00, GraphPad 
Software Inc., San Diego, CA, USA) for statistical analysis. 
Nitric oxide release was expressed as % of the nitric oxide release induced by untreated or 
LPS-stimulated cells respectively. Data are expressed as mean ± SEM; n represents the 
number of independent experiments. 
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Statistical analysis was performed by one-way analysis of variance (ANOVA) followed by 
Tukey Multiple Comparison Test. 
2.9.4 Materials and equipment 
Table 18: Nitric oxide release – Substances and consumables 
Substance/consumable Supplier 
DMEM high glucose, incl. glutamin 
PAA Laboratories GmbH, Pasching, 
Austria 
Fetal calf serum (FCS), heat inactivated Thermo Scientific, Waltham, USA 
Penicillin 10.000 units/streptomycin 10 mg 
PAA Laboratories GmbH, Pasching, 
Austria 
Griess reagent for nitrite Fluka, Buchs, Switzerland 
Lipopolysaccharide from E. coli 055:B5 Sigma-Aldrich, Steinheim, Germany 
Aminoguanidine hydrochloride Cayman Chemical, Ann Arbor, USA 
Microtiter multiwell plates, 96 well 
Sarstedt AG & Co., Nümbrecht, 
Germany 
Serological pipettes 
Sarstedt AG & Co., Nümbrecht, 
Germany 
Table 19: Nitric oxide release – Equipment 
Equipment Manufacturer 
Laminar Flow System Biowizard Kojair, Vilppula, Finland 
Binder CO2 Incubator CB150 WTB Binder, Tuttlingen, Germany 
Sunrise microplate reader Tecan, Grödig, Austria 
2.10 Cytotoxicity testing 
2.10.1 MTT-assay 
The MTT assay determines the viability of cells by mitochondrial reduction of yellow soluble 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium) to purple formazan in metabolically 
active cells. Briefly, after macrophages or macrophage-like cells were stimulated with LPS, the 
supernatant has been removed and remaining cells were treated with 100 µl MTT (0.3 mg/ml 
in PBS) per well for two hours. Triton X was used as control for complete cell death. After the 
incubation period, cells were lysed by addition of 100 µl lysis buffer. After complete cell lysis, 
the amount of resulting purple formazan was detected spectrophotometrically at 570 nm. 
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2.10.2 LDH-assay 
The LDH-assay is a colorimetric test to determine cell membrane integrity as an indicator of 
cell death. It is based on the reduction of nicotinamide adenine dinucleotide (NAD+) by 
cytosolic lactate dehydrogenase (LDH) which is released when membrane integrity is 
impaired. The resulting NADH is utilised by the enzyme diaphorase in the stoichiometric 
conversion of a yellow tetrazolium dye into a red formazan product, which can be detected 
spectrophotometrically. 
Thus, after differentiation to macrophage-like cells and stimulation with LPS, the collected cell 
free supernatant was incubated with the substrate solution (diaphorase/NAD). Triton X was 
used as control for complete cell death. After an incubation time of 30 minutes the enzymatic 
reaction was stopped by addition of hydrochloric acid (HCl, 1 N) and the formation of the red 
formazan was measured spectrophotometrically at 492 nm with a reference wave length at 
620 nm.  
2.10.3 Data analysis 
Recording of the extinction data was done using ADAP basic software (Anthos Mikrosysteme 
GmbH, Krefeld, Germany).  
Further data analysis was performed using Microsoft Excel (version 14.0, Microsoft 
cooperation, Redmond, WA, USA) and Graph Pad Prism (version 6.00, GraphPad Software 
Inc., San Diego, CA, USA) for statistical analysis. 
Metabolic activity and LDH-release were expressed as % of the metabolic activity or LDH-
release of untreated cells respectively. Data are expressed as mean ± SEM; n represents the 
number of independent experiments. 
Statistical analysis was performed by one-way analysis of variance (ANOVA) followed by 
Tukey Multiple Comparison Test. 
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2.10.4 Materials and equipment 
Table 20: Cytotoxicity testing - Substances and consumables 
Substance/consumable Supplier 
Hydrochloric acid (1 N HCl) Grüssing GmbH, Filsum, Germany 
Triton-X 100 Sigma-Aldrich, Steinheim, Germany 
Thiazolyl blue tetrazolium bromide (MTT) Sigma-Aldrich, Steinheim, Germany 
Cytotoxicity Detection Kit (LDH) 
Roche Diagnostics GmbH, Mannheim, 
Germany 
Serological pipettes 
Sarstedt AG & Co., Nümbrecht, 
Germany 
Table 21: Cytotoxicity testing - Substances and consumables – lysis buffer 
Substance Amount Supplier 
Lysis buffer 
Sodium dodecyl sulfate (SDS) 50.0 g Sigma-Aldrich, Steinheim, Germany 
Dimethylformamide (DMF)  80 ml  Grüssing GmbH, Filsum, Germany 
Aqua purificata ad 250 ml  
Table 22: Cytotoxicity testing - Equipment 
Equipment Manufacturer 
Laminar Flow Bench Biowizard Kojair® UniEquip, Leipzig, Germany 
Multi-gas incubator  
Sanyo Sales & Marketing Europe GmbH, 
Munich, Germany 
UV/VIS-spectrometer Anthos Reader 2010 
Anthos Mikrosysteme GmbH, Krefeld, 
Germany 
Vortex shaker Reax 2000 
Heidolph Instruments GmbH & Co. KG, 
Schwabach, Germany 
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2.11 Native human M1-macrophages  
2.11.1 Preparation of human monocytes and macrophage differentiation 
Whole blood was obtained from healthy volunteers after informed consent. Blood donation was 
performed at the Institute for Transfusion Medicine (Blood donation centre, Institute for 
Transfusion Medicine, Leipzig University Hospital).  
Monocytes were isolated using density gradient centrifugation. Thus, 25 ml whole blood 
(treated with citrate phosphate dextrose solution as anticoagulant) were layered on 20 ml Ficoll 
separating solution with a specific density of 1.077 g/ml (Biochrom AG, Berlin, Germany) and 
separated by centrifugation at 400x g (without break) for 20 minutes at room temperature. The 
interphase, containing peripheral blood mononuclear cells (PBMCs) like lymphocytes, 
monocytes and thrombocytes was carefully removed and washed twice with PBS. An 
additional centrifugation step at 100x g for 15 minutes with PBS was performed to separate 
thrombocytes which remain in the supernatant. A scheme illustrating the PBMC isolation 
process is presented in Figure 10. 
 
Figure 10: Isolation of peripheral blood mononuclear cells (PBMCs) by density gradient 
centrifugation (adapted from GE Healthcare) 
(1) Whole blood was obtained from healthy volunteers after informed consent. 
(2) Ficoll separation solution with a specific density of 1.077 g/ml was layered under the whole blood 
fraction.  
(3) After density gradient centrifugation (400x g; 20 minutes; without break) the peripheral blood 
mononuclear cell (PBMC) fraction was separated and collected. 
For the isolation of monocytes from the PBMC fraction, Monocytes isolation Kit II (Miltenyi 
Biotec GmbH, Bergisch Gladbach, Germany), an indirect labelling system, was used according 
to manufacturer’s instructions. In a first step, unspecific binding sites on the cell surface were 
blocked using blocking reagents. Non-monocytes, i.e. T cells, B cells, dendritic cells and 
basophils were afterwards indirectly magnetically labelled using a mixture of biotin-conjugated 
antibodies (primary labelling: anti-CD3, anti-CD7, anti-CD16, anti-CD19, anti-CD56, anti-
CD123 and glycophorin A) and anti-biotin microbeads (secondary labelling).  
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Using magnetic separation columns (LS MACS Columns, Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany), labelled non-monocytic cells were retained, while unlabelled monocytes 
were eluted and collected.  
Quality control for purity of isolated monocytes 
Purity of the enriched monocyte fraction was evaluated by flow cytometry using fluorochrome-
conjugated CD14-antibodies (Anti-Human CD14 PE; eBioscience, Frankfurt, Germany). Thus, 
5 x 105 cells were suspended in 50 µl PBS containing bovine serum albumin (BSA, 1 %; Sigma 
Aldrich, Steinheim, Germany) and 5 µl antibody solution as well as isotype control (Mouse 
IgG1 K Isotype Control PE; eBioscience, Frankfurt, Germany) was added and incubated for 
30 minutes in the dark. After two washing steps, cells were suspended in phosphate buffered 
saline (PBS; Amresco, Solon, OH, USA) and analysed by flow cytometry (BD FACSCaliburTM, 
BD Bioscience, Heidelberg, Germany). 
 
Figure 11: Detection of CD14 in isolated human monocytes. 
Cells were incubated with anti-CD14 for 30 minutes and analysed using flow cytometry. [A] shows size 
and granularity of isolated monocytes. Fluorescence intensity of 104 cells was measured at 530 nm. 
[B] 80.94 % (± 6.7; n = 3) of the detected cell were CD14-positive monocytes. 
Differentiation to M1-macrophages 
Isolated monocytes were counted using a Neubauer improved counting chamber, adjusted to 
1 x 106 cells/ml in RPMI 1640 supplemented with fetal calf serum (FCS, 10 %; Sigma-Aldrich, 
Steinheim, Germany), penicillin/streptomycin (P/S, 1 %; Sigma-Aldrich, Steinheim, Germany) 
and cultured at standard cell culture conditions.  
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For the differentiation to macrophages, granulocyte-macrophage colony-stimulating factor 
(GM-CSF; Life Technologies, Carlsbad, CA, USA) in a concentration of 100 ng/ml was added 
to the culture medium. 
Monocytes were allowed to differentiate for 6 days at 37°C in 5 % CO2 humidified air, whereby 
a complete medium change was performed at day 2 and 4. 
2.11.2 LPS/IFNγ stimulation and incubation of plant extracts 
After differentiation to macrophages, the isolated cells were stimulated with a mixture of 
100 ng/ml LPS (lipopolysaccharide from E. coli 0111:B4; Sigma-Aldrich, Steinheim, Germany) 
and 10 ng/ml interferon-γ (IFNγ, Biomol, Hamburg, Germany) for 24 hours to polarise 
macrophages towards the pro-inflammatory M1-subtype as it has been demonstrated by 
Jaguin  et al. and to induce an inflammatory response (Jaguin et al. 2013).  
In order to determine the influence of the plant extracts on the inflammatory response, the 
substances were incubated simultaneously with the LPS/IFNγ mixture in their respective 
concentration. Based on previous cell culture experiments, optimal incubation conditions and 
concentrations were determined. Subsequently, ethanolic myrrh extract (30 µg/ml), aqueous 
myrrh extract (500 µg/ml), chamomile flower extract (200 µg/ml) and coffee charcoal extract 
(500 µg/ml) were tested. All samples were incubated at standard cell culture conditions (37°C 
in 5 % CO2 humidified air) for 24 hours.  
2.11.3 RNA isolation 
After LPS/IFNγ stimulation and substance incubation, total RNA was isolated from adherent 
macrophages by column separation using RNeasy Mini Kit (Qiagen, Hilden, Germany) 
according to manufacturer’s instructions.  
Thus, after cell lysis with lysis buffer, lysates were collected and transferred to the separation 
columns. During centrifugation of the columns (8000x g; 15 s), total RNA bound to the column 
membrane. After three washing steps, residual liquid was removed by centrifugation for 
2 minutes at 9000x g. For elution of the total RNA, 30 µl RNase free water was added to the 
column and incubated for 2 minutes. In a final centrifugation step (8000x g; 1 min), RNA was 
eluted from the column membrane, quickly frozen and stored at -80°C until further use. 
Before further processing, RNA quality and integrity was determined electrophoretically at the 
Core Unit DNA Technologies of the Interdisciplinary Centre for Clinical Research (IZKF, 
Medical Faculty, University of Leipzig) using the Agilent RNA 6000 Nano Kit (Agilent 
Technologies, Inc., Santa Clara, CA, USA). Thus, RNA agarose-gel electrophoresis was 
performed to separate RNA by size. Subsequently, the RNA integrity number (RIN) was 
determined (Figure 4). The RIN allows for classification of total RNA, based on a numbering 
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system from 1 to 10, with 1 being the most degraded profile and 10 being the most intact. 
Based on this assessment the quality of most of the RNA samples was found sufficient for 
gene expression analysis. However, the quality of isolated RNA from macrophages treated 
with aqueous myrrh extract (sample-ID: MYA500) was found reduced with a RIN value of 3.10. 
This could be related to the fact, that RNA yield was comparably low after isolation as well. In 
this case, centrifugal vacuum evaporation was performed to concentrate the RNA sample 
before gene expression analysis. 
  
Figure 12: Quality assessment of total RNA by agarose-gel electrophoresis. 
Electropherogram and RNA Integrity Number (RIN) of mRNA samples from human macrophages 
incubated with LPS/IFNγ (LPS) and ethanolic myrrh extract (MY30*), coffee charcoal extract 
(CC500*), chamomile flower extract (KA200*) or aqueous myrrh extract (MYA500*) or single 
incubation with ethanolic myrrh extract (MY30), coffee charcoal (CC500), chamomile flower extract 
(KA200) or aqueous myrrh extract (MYA500) for 24 hours. All samples show specific lines for 28S- 
and 18S-ribosomal RNA. 
2.11.4 cDNA synthesis 
Synthesis of cDNA was performed at the Core Unit DNA Technologies of the Interdisciplinary 
Centre for Clinical Research (IZKF, Medical Faculty, University of Leipzig). Briefly, poly(A) RNA 
(mRNA) was amplified in a total RNA sample using MessageBOOSTER™ cDNA Synthesis Kit 
for qPCR (Epicentre Technologies Corporation, Madison, WI, USA). Using this method, the 
poly(A) RNA component of a total RNA sample is reverse transcribed into first-strand cDNA 
using SuperScript III Reverse Transcriptase (Invitrogen, Carlsbad, California, USA). Next, the 
RNA component of the cDNA:RNA hybrid is digested into small RNA fragments by RNase H 
and the second strand cDNA is synthesised. During this in vitro transcription the double 
stranded cDNA is transcribed and high yields of antisense-RNA (aRNA) are obtained. In a 
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clean-up process the aRNA is purified by spin column chromatography using RNeasy 
MiniElute Cleanup (Qiagen, Hilden, Germany). Finally, the purified aRNA is reverse 
transcribed into first-strand cDNA using SuperScript III Reverse Transcriptase (Invitrogen, 
Carlsbad, California, USA), quickly frozen and stored at -80°C until further use. 
2.11.5 Microarray gene expression analysis 
Gene expression analysis was performed for all plant extracts in double determination at the 
Core Unit DNA Technologies of the Interdisciplinary Centre for Clinical Research (IZKF, 
Medical Faculty, University of Leipzig) using a HumanHT-12 v4 Expression BeadChip (Illumina 
Inc., San Diego, CA, USA). In the first gene expression analysis procedure (20/03/2014), 
ethanolic myrrh extract (30 µg/ml) and coffee charcoal extract (500 mg/ml) were tested. 
Chamomile flower extract (200 µg/ml) and aqueous myrrh extract (500 µg/ml) were tested in a 
second gene expression analysis procedure (17/04/2014). 
2.11.6 Data analysis 
Results of microarray gene expression analysis was provided as text-file including information 
such as the distinct gene ID (Probe_ID), gene symbol, and the corresponding signal values. 
Processing of raw data was performed using Microsoft Excel (version 14.0, Microsoft 
cooperation, Redmond, WA, USA). Thus, double determined values were averaged and 
values below 4.0 were set 1.0 for correction of background noise. For the identification of genes 
that were affected by the particular treatments, ratios were determined to detect changes 
relative to untreated cells or LPS/IFNγ-treated cells. 
Classification of affected genes was performed using the software based gene ontological 
enrichment analysis ‘WEB-based GEne SeT AnaLysis Toolkit’ (WebGestalt software (version 
1/30/2013) provided by the Vanderbilt University. Genes that were up- or down-regulated by 
factor ≥ 10 were entered into the platform using their Reference Sequence (RefSeq)-ID. A 
complete list of all analysed genes was used as reference data set. Statistical analysis was 
performed using hypergeometric test followed by Multiple Test Adjustment according to 
Benjamini-Hochberg (BH) which reported an adjusted p-value (adjP). Results were clustered 
and mapped on the base of the “Gene Ontology”. The Gene Ontology allows the annotation of 
homologous gene and protein sequences in multiple organisms using a common vocabulary 
for the description of the biological process, molecular function and cellular component of 
genes (Ashburner et al. 2000).  
Gene ontological (GO) categories with an adjusted p-value ≤ 0.05 were considered 
significantly enriched. If more than ten categories were significantly enriched, only categories 
with the ten lowest significance values were highlighted to allow better visualisation.  
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2.11.7 Methods and equipment 
Table 23: Native human M1-macrophages - Substances and consumables 
Substance/consumable Supplier 
Ficoll separating solution Biochrom AG, Berlin, Germany 
Anti-Human CD14-PE eBioscience, San Diego, CA, USA 
Phosphate Buffered Saline, PBS (1x) Amresco, Solon, OH, USA 
Albumin from bovine serum Sigma Aldrich, Steinheim, Germany 
Mouse IgG1 K Isotype Control PE eBioscience, Frankfurt, Germany 
RPMI medium 1640 (1x), with glutamine 
Gibco, Life Technologies, Thermo Fisher 
Scientific, Carlsbad, CA, USA 
Newborn calf serum (FCS), heat inactivated Sigma Aldrich, Steinheim, Germany 
Penicillin 10.000 units/streptomycin 10 mg Sigma Aldrich, Steinheim, Germany 
Recombinant GM-CSF Life Technologies, Carlsbad, CA, USA 
Lipopolysaccharide from E. coli 0111:B4 Sigma-Aldrich, Steinheim, Germany 
Interferon gamma, human recombinant Biomol, Hamburg, Germany 
Ethylenediaminetetraacetic acid (EDTA) Sigma Aldrich, Steinheim, Germany 
Anti-Human CD80-PE eBioscience, San Diego, CA, USA 
Anti-Human CD284-PE eBioscience, San Diego, CA, USA 
Anti-Human CD163-PE eBioscience, San Diego, CA, USA 
Monocytes isolation Kit II 
Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany 
LS MACS Columns 
Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany 
RNeasy Mini Kit Qiagen, Hilden, Germany 
Agilent RNA 6000 Nano Kit 
Agilent Technologies, Inc., Santa Clara, 
CA, USA 
NunclonTM Surface, 6 wells Nunc, Langenselbold, Germany 
Serological pipettes Sarstedt AG & Co., Nümbrecht, Germany 
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Table 24: Native human M1-macrophages - Equipment 
Equipment Manufacturer 
Centrifuge ‘Laborfuge 400R’ 
Heraeus Holding GmbH, Hanau, 
Germany 
BD FACSCalibur BD Bioscience, Heidelberg, Germany 
Agilent 2100 Bioanalyzer 
Agilent Technologies, Inc., Santa Clara, 
CA, USA 
Vacuum Concentrator, Uniequip Univapo 
100 H 
UniEquip Laborgerätebau- und Vertriebs 
GmbH, Planegg, Germany 
Illumina HighScan Array Scanner Illumina, San Diego, CA, USA 
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3 Results 
3.1 Spasmolytic activity of Myrrhinil-Intest® components 
3.1.1 Spasmolytic activity of chamomile flower extract 
For investigation of spasmolytic activity, isometric contractions were measured using an organ 
bath equipment. They were induced by acetylcholine (ACh) applied directly into the organ 
baths with a final bath concentration of 1 mM. 
 
Figure 13: Influence of chamomile flower extract (KA) on acetylcholine (ACh)-induced 
contractions in untreated ileum/jejunum preparations (A: representative original recording; B: 
statistical analysis). 
ACh (1 mM)-induced contractions were determined using isometric tension measurement. Chamomile 
flower extract (KA, 8.75 – 280 µg/ml) was applied two minutes prior induction of contraction. ACh-
induced contractions were determined using isometric tension measurement. Data are presented as 
mean ± SEM; the vertical line in (A) represents basal tone; ** p<0.01 vs. control, *** p<0.001 vs. 
control; n = 5-10. 
Application of chamomile flower extract (KA, 8.75 – 280 µg/ml) into the organ bath two minutes 
prior induction of contraction resulted in a concentration-dependent decrease of ACh-induced 
contraction down to 56 % ± 5.2 (% control) (Figure 13; 140 µg/ml KA: 78.06±8.2, p<0.01; 
210 µg/ml KA: 63.48±5.9, p<0.001; 280 µg/ml KA: 56.11±5.2, p<0.001; in % control). 
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To investigate spasmolytic activity in inflamed tissue, inflammation was induced in vitro and 
ACh-induced contractions were assessed (Figure 14). 
 
Figure 14: Influence of chamomile flower extract (KA) on acetylcholine (ACh)-induced 
contractions in inflamed ileum/jejunum preparations (A: representative original recording; B: 
statistical analysis). 
ACh (1 mM)-induced contractions were determined using isometric tension measurement. Chamomile 
flower extract (KA, 8.75 – 280 µg/ml) was applied two minutes prior induction of contraction. Data are 
presented as mean ± SEM; the vertical line in (A) represents basal tone; ** p<0.01 vs. control, 
*** p<0.001 vs. control; n = 5-10. 
Application of chamomile flower extract (KA, 8.75 – 280 µg/ml) resulted in a concentration-
dependent decrease of ACh-induced contraction down to 59 % ± 5.2 (% control) (Figure 14; 
140 µg/ml KA: 74.4±6.0, p<0.01; 210 µg/ml KA: 62.54±5.0, p<0.001; 280 µg/ml KA: 59.23±5.4, 
p<0.001; in % control). 
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Figure 15: Concentration-response curves in untreated and inflamed ileum/jejunum 
preparations. 
Effect of chamomile flower extract (8.75 – 280 µg/ml) on ACh-induced contraction in inflamed and 
untreated ileum/jejunum preparations. Data are presented as mean ± SEM and non-linear regression 
curve for untreated (■) and inflamed (▲) preparations (n = 5-10). 
Comparing the concentration-response curves of the chamomile flower extract influence on 
ACh-induced contractions between untreated and inflamed preparations, no significant 
difference was found with regard to the half maximal inhibitory concentration (Figure 15; IC50 – 
untreated preparations: 160.7 µg/ml; IC50 – inflamed preparations: 126.1 µg/ml; Comparison 
of Fits [IC50]: p=0.41). 
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3.1.2 Spasmolytic activity of ethanolic myrrh extract 
Effects on acetylcholine-induced contraction 
 
Figure 16: Influence of ethanolic myrrh extract (MY) on acetylcholine (ACh)-induced 
contractions in untreated ileum/jejunum preparations (A: representative original recording; B: 
statistical analysis). 
ACh (1 mM)-induced contractions were determined using isometric tension measurement. Ethanolic 
myrrh extract (50 – 1000 µg/ml) was applied two minutes prior induction of contraction. Data are 
presented as mean ± SEM; the vertical line in (A) represents basal tone; *** p<0.001 vs. control; n = 3. 
Application of ethanolic myrrh extract (50 – 1000 µg/ml) into the organ bath two minutes prior 
induction of contraction resulted in a concentration-dependent decrease of ACh-induced 
contraction down to 10 % ± 5.2 (% control) (Figure 16; 50 µg/ml MY: 68.13±4.1; 80 µg/ml MY: 
72.95±1.5; 100 µg/ml MY: 58.23±6.4; 300 µg/ml MY: 39.70±6.4; 500 µg/ml MY: 25.60±0.67; 
600 µg/ml MY: 26.70±5.1; 800 µg/ml MY: 10.10±1.1; 1000 µg/ml MY: 13.57±3.4; p<0.001; in 
% control). 
To investigate spasmolytic activity in inflamed tissue, inflammation was induced in vitro and 
ACh-induced contractions were assessed (Figure 17). 
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Figure 17: Influence of ethanolic myrrh extract (MY) on acetylcholine (ACh)-induced 
contractions in inflamed ileum/jejunum preparations (A: representative original recording; B: 
statistical analysis). 
ACh (1 mM)-induced contractions were determined using isometric tension measurement. Ethanolic 
myrrh extract (50 – 1000 µg/ml) was applied two minutes prior induction of contraction. Data are 
presented as mean ± SEM; the vertical line in (A) represents basal tone (); * p<0.05 vs. control, 
** p<0.01 vs. control, *** p<0.001 vs. control; n = 3. 
Application of ethanolic myrrh extract (50 – 1000 µg/ml) to the organ bath two minutes prior 
induction of contraction resulted in a concentration-dependent decrease of ACh-induced 
contraction down to 14 % ± 4.3 (% control) (Figure 17; 50 µg/ml MY: 78.48±3.3; 80 µg/ml MY: 
73.10±0.6; 100 µg/ml MY: 74.50±5.8; 300 µg/ml MY: 47.50±4.1; 500 µg/ml MY: 31.16±8.8; 
600 µg/ml MY: 27.45±3.5; 800 µg/ml MY: 13.9±4.3; 1000 µg/ml MY: 15.82±2.8; p<0.001; in 
% control). 
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Figure 18: Concentration-response curves in untreated and inflamed ileum/jejunum 
preparations. 
Effect of ethanolic myrrh extract (50 – 1000 µg/ml) on ACh-induced contraction in inflamed and 
untreated ileum/jejunum preparations. Data are presented as mean ± SEM and non-linear regression 
curve for untreated (■) and inflamed (▲) preparations (n = 6). 
Comparing the concentration-response curves of the ethanolic myrrh extract influence on ACh-
induced contractions between untreated and inflamed preparations, higher concentrations 
were necessary in inflamed tissue to induce half maximal inhibition. (Figure 18; IC50 – 
untreated preparations: 157.7 µg/ml; IC50 – inflamed preparations: 227.6 µg/ml; Comparison 
of Fits [IC50]: p=0.0047). 
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Effects on basal muscular tone 
To determine the effect of ethanolic myrrh extract on basal muscular tone, isometric tension 
measurement was performed and muscular tone was recorded.  
 
Figure 19: Effect of ethanolic myrrh extract (MY; 0.2 mg/ml) on basal muscular tone of 
untreated rat ileum/jejunum preparations. 
Isometric tension measurement was performed with isolated rat ileum/jejunum preparations 
(representative original recording). Application of ethanolic myrrh extract (MY; 0.2 mg/ml) at minute 
30 directly to the organ baths decreased basal muscular tone. Subsequent cumulative administration 
of L-type calcium channel agonist Bay K8644 (10-10 – 10-7 M) reversed the decrease in muscular tone. 
Application of ethanolic myrrh extract in a concentration of 0.2 mg/ml directly into the organ 
baths resulted in a decrease in muscle tone (Figure 19). After cumulative application of the 
calcium channel agonist Bay K8644 (10-10 – 10-7 M), the effect could be antagonised and the 
muscle tone was restored to its initial level. 
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Figure 20: Effect of nimodipine (0.01 M) on basal muscular tone of untreated rat ileum/jejunum 
preparations. 
Isometric tension measurement was performed with isolated rat ileum/jejunum preparations 
(representative original recording). Application of nimodipine at minute 30 directly to the organ baths 
decreased basal muscular tone. Subsequent cumulative administration of L-type calcium channel 
agonist Bay K8644 (10-8 – 10-5 M) reversed the decrease in muscular tone. 
Application of the well-known calcium channel antagonist nimodipine (0.01 M) led likewise to 
an inhibition of basal muscular tone (Figure 20). After cumulative application of the calcium 
channel agonist Bay K8644 (10-8 – 10-5 M), the effect was antagonised and the muscle tone 
was restored to its initial level. 
 
Figure 21: Bay K8644 concentration-response curves with and without antagonist (A: 
nimodipine, B: ethanolic myrrh extract) 
Effect of pre-treatment with nimodipine (A, 0.01 M) and ethanolic myrrh extract (B, MY 0.15 mg/ml) on 
the agonistic (Bay K8644, 10-11 – 10-5 M) concentration-response curve measuring basal muscular 
tone of rat ileum/jejunum preparations. Data are presented as mean ± SEM and non-linear regression 
curve with and without pre-treatment of nimodipine and MY respectively, n = 8-10. 
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Concentration-response curves of Bay K8644 with and without pre-treatment of nimodipine (A) 
and ethanolic myrrh extract (B) are presented in Figure 21. Ethanolic myrrh extract in a 
concentration of 0.15 mg/ml led to a significant EC50 shift from 5.9E-8 M to 3.7E-7 M 
(Comparison of Fits [IC50; Emax]: p=0.0008). In comparison pre-treatment with nimodipine 
(0.01 mM) resulted in an EC50 shift from 5.7E-8 M to 7.4E-7 M (Comparison of Fits [IC50; 
Emax]: p<0.0001). The maximum effect of the agonist Bay K8644 was not significantly altered 
in this concentrations. 
 
Additionally, increasing concentrations of ethanolic myrrh extract were tested to get a more 
precise picture of the antagonistic properties (Figure 22). Furthermore, these experiments 
were carried out using untreated (A) and inflamed (B) intestinal preparations. 
 
Figure 22: Bay K8644 concentration-response curves after pre-treatment with increasing 
concentrations of ethanolic myrrh extract. 
Effect of pre-treatment with ethanolic myrrh extract (0.15 – 0.35 mg/ml) on the agonistic 
(Bay K8644, 10-9 - 10-6 M) concentration-response curve measuring basal muscular tone of untreated 
(A) and inflamed (B) rat ileum/jejunum preparations. Data are presented as mean ± SEM and non-
linear regression curves; the table shows maximum effect (Emax) and EC50-values of the agonistic 
concentration-response relation dependent on pre-treatment with increasing myrrh extract 
concentrations (n = 4). 
Pre-treatment with increasing concentrations of ethanolic myrrh extract (MY) significantly 
altered the Bay K8644 concentration-response relation in untreated preparations with regard 
to half maximal effective concentration (EC50) and maximum effect (Emax), whereby a right-
ward shift of the concentration-response curve as well as a depression of maximum effect 
could be observed (Figure 22A; agonist only: EC50=6.0E-8, Emax=100.1 %; 0.15 mg/ml MY: 
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EC50=3.7E-7, Emax=96.14 %; 0.25 mg/ml MY: EC50=1.6E-7, Emax=57.13 %; 0.35 mg/ml 
MY: EC50=3.2E-7, Emax=15.86 %; Comparison of Fits [EC50; Emax] p=0.0008). 
In inflamed preparations, the concentration-response curve of Bay K8644 after pre-treatment 
with increasing concentrations of ethanolic myrrh extract was likewise significantly altered 
(Figure 22B; agonist only: EC50=4.4E-8, Emax=100.3 %; 0.15 mg/ml MY: EC50=6.9E-7, 
Emax=127.1 %; 0.25 mg/ml MY: EC50=2.3E-7, Emax=98.70 %; 0.35 mg/ml MY: 
EC50=1.7E-6, Emax 25.78 %; Comparison of Fits [EC50; Emax] p=0.007).  
 
Quantitative analysis of the shift of agonistic concentration-response curve representing 
competitive antagonistic effects was performed by calculating the pA2 value using Schild plot. 
Equally, a quantification of non-competitive effects was done by calculation of the pD2, based 
on the extent of Emax depression. 
 
Figure 23: Schild analysis for different concentrations of ethanolic myrrh extract. 
Analysis of EC50 shift (A) and Emax depression (B) by Schild analysis for increasing concentrations of 
ethanolic myrrh extract (0.15 - 0.35 mg/ml). Presented are linear regression and 95 % confidence 
interval (dotted line); pA2 = 0.93; pD2 = 0.56. 
The graphic representation of these calculations is presented in Figure 23 for untreated 
preparations with a pA2-value of 0.93. This corresponds to a concentration of 0.11 mg/ml 
ethanolic myrrh extract, which induced a 2-fold right-ward shift of the agonistic concentrations-
response curve. The calculated pD2-value of 0.58 corresponds to a concentration of 
0.26 mg/ml ethanolic myrrh extract, which decreased the maximum effect induced by the 
agonist down to 50 %.  
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3.1.3 Spasmolytic activity of coffee charcoal extract 
 
Figure 24: Influence of coffee charcoal extract (CC) on ACh-induced contractions in untreated 
ileum/jejunum preparations (A: representative original recording; B: statistical analysis). 
ACh (1 mM)-induced contractions were determined using isometric tension measurement. Coffee 
charcoal extract (0.35 – 700 µg/ml) was applied two minutes prior induction of contraction. Data are 
presented as mean ± SEM; the vertical line in (A) represents basal tone; n = 8. 
No effect on ACh-induced contraction was observed, after coffee charcoal extract (0.35 – 
700 µg/ml) was applied directly into the organ baths two minutes prior induction of contraction 
(Figure 24). 
To investigate spasmolytic activity in inflamed tissue, inflammation was induced in vitro and 
ACh-induced contractions were assessed (Figure 25). Likewise, no effect on ACh-induced 
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contraction in inflamed tissue was observed, after coffee charcoal extract (0.35 – 700 µg/ml) 
application. 
 
Figure 25: Influence of coffee charcoal extract (CC) on ACh-induced contractions in inflamed 
ileum/jejunum preparations (A: representative original recording; B: statistical analysis). 
Tonic contraction was induced in inflamed isolated rat ileum/jejunum preparations by application of 
ACh (1 mM). Coffee charcoal extract (0.35 – 700 µg/ml) was applied two minutes prior induction of 
contraction. Data are presented as mean ± SEM; the vertical line in (A) represents basal tone; n = 8. 
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3.2 Anti-inflammatory activity of Myrrhinil-Intest® components 
3.2.1 Anti-inflammatory activity of chamomile flower extract 
Effect of chamomile flower extract on TNBS-induced morphological damage 
 
Figure 26: Effect of chamomile flower extract (3 mg/ml) on TNBS-induced morphological 
damage. 
Rat ileum preparations were incubated with TNBS (100 mM) and chamomile flower extract (KA; 
3 mg/ml) for 30 minutes and mucosa layer thickness was determined morphometrically after HE-
staining. TNBS-incubation alone served as positive control. Presented are representative original 
images (A-C) and statistical analysis (D) with mean ± SEM; * p<0.05 vs. untreated control, # p<0.05 vs. 
TNBS; n = 4. 
Incubation with TNBS (100 mM; 30 minutes) induced a morphological damage expressed by 
a decrease in mucosa layer thickness down to 76.86 % ± 6.8 compared to untreated control 
(p<0.05). Simultaneous incubation of TNBS and chamomile flower extract (KA, 3 mg/ml) 
inhibited the TNBS-induced decrease of mucosa layer thickness (Figure 26; 3 mg/ml KA: 
102.1 % ± 8.1, p<0.05 vs. TNBS treatment). 
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Figure 27: Effect of chamomile flower extract (30 mg/ml) on TNBS-induced morphological 
damage. 
Rat ileum preparations were incubated with TNBS (10 mM) and chamomile flower extract (KA; 
30 mg/ml) for 30 minutes and mucosa layer thickness was determined morphometrically after HE-
staining. Single TNBS-incubation served as positive control. Presented are representative original 
images (A-C) and statistical analysis (D) with mean ± SEM; * p<0.05 vs. untreated control; n = 4. 
In this series of experiments the incubation with TNBS (100 mM; 30 minutes) induced a 
morphological damage expressed by a decrease in mucosa layer thickness down to 85.26 % 
± 2.6 compared to untreated control (p<0.05). Simultaneous incubation of TNBS and 
chamomile flower extract (KA, 30 mg/ml) led to a comparable decrease of mucosa layer 
thickness as observed with TNBS alone (Figure 27; 30 mg/ml KA: 78.66 % ± 3.2, p<0.05 vs. 
control). 
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Effect of chamomile flower extract on TNBS-induced contractility decrease 
 
Figure 28: Effect of chamomile flower extract on TNBS-induced contractility decrease 
(A: representative original recording; B: statistical analysis). 
Rat ileum/jejunum preparations were incubated with TNBS (10 mM) and chamomile flower extract 
(KA; 1 - 30 mg/ml) for 30 minutes and ACh-induced contractions were determined. TNBS-incubation 
alone served as positive control. Representative original recording (A) and statistical analysis (B) with 
mean ± SEM (n = 12); the vertical line in (A) represents basal tone; * p<0.01 vs. untreated control; 
# p<0.05 vs. TNBS. 
Incubation with TNBS (10 mM; 30 minutes) induced a decrease in ACh-induced contraction 
down to 70.95 % ± 3.4 compared to untreated control (p<0.05). Simultaneous incubation of 
TNBS and chamomile flower extract (KA, 1 – 30 mg/ml) led to a significant inhibition of 
contractility decrease in concentrations of 3 and 10 mg/ml, resulting in an inverted U-shape 
concentration-effect relation (Figure 28; 1.0 mg/ml KA: 85.22±3.4; 3.0 mg/ml KA: 96.88±10.5, 
p<0.05 vs. TNBS; 10.0 mg/ml KA: 99.98±16.5, p<0.05 vs. TNBS; 30.0 mg/ml KA: 64.42±9.8). 
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Effect of chamomile flower extract on TNBS-induced TNFα gene expression 
The influence of chamomile flower extract on TNBS-induced overexpression of TNFα-mRNA 
in rat small intestinal preparations is presented in Figure 29. 
 
Figure 29: Effect of chamomile flower extract on TNBS-induced TNFα gene expression 
Rat ileum/jejunum preparations were incubated with TNBS (10 mM) and chamomile flower extract 
(KA; 0.1 - 100 mg/ml) for 3 hours and the amount of TNFα-mRNA expression was analysed using real 
time PCR. Single TNBS-incubation served as positive control. Presented are mean ± SEM (n = 6) of 
TNFα-mRNA expression in relation to untreated control; * p<0.01 vs. untreated control; # p<0.05 vs. 
TNBS. 
Incubation with TNBS (10 mM; 3 hours) induced a 4-fold increase in TNFα-mRNA expression 
compared to untreated control (p<0.01). Simultaneous incubation of TNBS and chamomile 
flower extract (KA, 0.1 – 100 mg/ml) led to a significant inhibition of the TNFα-mRNA 
expression (Figure 29; 0.1 mg/ml KA: 0.97±0.3, p<0.05; 1.0 mg/ml KA: 1.37±0.5; 10 mg/ml KA: 
1.15±0.2, p<0.05; 100 mg/ml KA: 1.08±0.4, p<0.05; -fold compared to untreated control). 
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Effect of chamomile flower extract on LPS-induced TNFα release from THP-1 cells 
To determine the influence of chamomile flower extract on LPS-induced TNFα release, LPS-
stimulated (100 ng/ml), differentiated THP-1cells were incubated with chamomile flower extract 
(KA, 0.1 – 1000 µg/ml) for four hours. Subsequently, TNFα amount in cell supernatant was 
determined by ELISA. Differentiated THP-1 cells without LPS stimulation (u.c.), differentiated 
cells that were solely stimulated with LPS (LPS; 100 ng/ml) and differentiated cells that were 
treated with LPS and the anti-inflammatory glucocorticoid budesonide (Bud; 1 nM) were 
additionally tested as controls. TNFα release of LPS-stimulated THP-1 cells was set 100 %. 
 
Figure 30: Effect of chamomile flower extract on LPS-induced TNFα release from THP-1 cells. 
Differentiated THP-1 cells were treated with LPS (100 ng/ml) and chamomile flower extract (KA; 0.1 – 
1000 µg/ml) and incubated for four hours. TNFα release was determined by ELISA. Budesonide (Bud, 
1 nM) served as positive control. Data are presented as mean ± SEM; * p<0.05 vs. untreated control 
(u.c.), # p<0.01 vs. LPS; n = 8-10. 
LPS (100 ng/ml) significantly increased TNFα release in differentiated THP-1 cells (Figure 30; 
u.c.: 9.17 % ± 1.3; LPS: 100 %, p<0.0001). After simultaneous treatment with budesonide 
(1 nM), TNFα release was significantly decreased compared to single LPS stimulation (Figure 
30; LPS: 100 %, Bud: 12.5 % ± 1.5; p<0.0001). DMSO in applied concentrations had no 
influence on TNFα release. 
Chamomile flower extract led to a concentration-dependent decrease in TNFα release down 
to 28 % ± 8.7 (Figure 30; 0.1 µg/ml KA: 102.4±6.0; 1 µg/ml KA: 99.24±1.3; 10 µg/ml KA: 
91.38±6.1; 50 µg/ml KA: 74.03±16.0; 100 µg/ml KA: 81.1±7.1, p<0.01; 200 µg/ml KA: 
53.69±24.6; 500 µg/ml KA: 43.71±19.8, p<0.01; 1000 µg/ml KA: 28.28±8.7, p<0.0001; in % 
LPS-treatment). 
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Figure 31: Effect of chamomile flower extract on metabolic activity (A) and LDH-release (B) of 
THP-1 cells. 
Differentiated THP-1 cells were treated with LPS (100 ng/ml) and chamomile flower extract (KA; 0.1 – 
1000 µg/ml) and incubated for four hours. Metabolic activity was determined by MTT-assay; LDH-
assay was performed to determine LDH-release. Data are presented as mean ± SEM (n = 8-10); 
** p<0.01 vs. untreated control (u.c.). 
To evaluate the viability of the cells used for determination of TNFα release, MTT-assay and 
LDH-assay were performed after treatment with the respective substances (Figure 31). 
Cell viability expressed as metabolic activity of differentiated THP-1 cells was not influenced 
after simultaneous incubation with LPS (100 ng/ml) and budesonide (1 nM). Increasing 
concentrations of chamomile flower extract did not alter cell viability in a concentration range 
of 0.1 – 100 µg/ml compared to untreated control. However, the highest concentration 
decreased metabolic activity to 69.84 % ± 4.8 (p<0.0001) compared to untreated control. 
LDH-release was not influenced by treatment with LPS (100 ng/ml) or simultaneous treatment 
with budesonide (1 nM) or chamomile flower extract (0.1 – 1000 µg/ml). 
To realise a distinction between the inhibition of TNFα release and influence of metabolic 
activity, a selectivity index was determined. Therefore, the concentration-response curves for 
TNFα release and metabolic activity were evaluated and half maximal inhibitory concentrations 
(IC50) were calculated (Figure 32). 
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Figure 32: Concentration-response curves of chamomile flower extract effect on LPS-induced 
TNFα release and metabolic activity 
To determine the selectivity index the concentration-response curves and IC50-values, for TNFα 
release (IC50 B) and metabolic activity (IC50 A) were ascertained by non-linear regression. Data are 
presented as mean ± SEM and non-linear regression curves for TNFα release (▲) and metabolic 
activity (■). 
Chamomile flower extract reduced TNFα release with an IC50-value of 438.8 µg/ml and 
metabolic activity with an IC50-value of 3106 µg/ml. The resulting selectivity index (SI = 7.08) 
indicates that reduction of metabolic activity occurs in 7-fold higher concentrations compared 
to reduction of TNFα release. 
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3.2.2 Anti-inflammatory activity of myrrh 
Effect of aqueous and ethanolic myrrh extract on TNBS-induced morphological damage 
 
Figure 33: Effect of aqueous myrrh extract on TNBS-induced morphological damage. 
Rat ileum preparations were incubated with TNBS (100 mM) and aqueous myrrh extract (MYA; 
1000 µg/ml) for 30 minutes and mucosa layer thickness was determined morphometrically after HE-
staining. TNBS-incubation alone served as positive control. Presented are representative original 
images (A-C) and statistical analysis (D) with mean ± SEM; * p<0.0001 vs. untreated control, # p<0.01 
vs. TNBS; n = 4. 
Incubation with TNBS (100 mM; 30 minutes) induced a morphological damage expressed by 
a decrease in mucosa layer thickness down to 84.79 % ± 2.0 compared to untreated control 
(p<0.0001). Simultaneous incubation of aqueous myrrh extract (MYA, 1 mg/ml) inhibited the 
TNBS-induced decrease of mucosa layer thickness (Figure 33; 1 mg/ml MYA: 102.4 % ± 4.1, 
p<0.01 vs. TNBS treatment). 
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Figure 34: Effect of ethanolic myrrh extract on TNBS-induced morphological damage. 
Rat ileum preparations were incubated with TNBS (100 mM) and ethanolic myrrh extract (MY; 
150 µg/ml) for 30 minutes and mucosa layer thickness was determined morphometrically after HE-
staining. TNBS-incubation alone served as positive control. Presented are representative original 
images (A-C) and statistical analysis (D) with mean ± SEM; * p<0.01; n = 4. 
The influence of ethanolic myrrh extract (0.15 mg/ml) on TNBS-induced morphological damage 
in rat ileum preparations is presented in Figure 34. Incubation with TNBS (100 mM; 30 minutes) 
induced a morphological damage expressed by a decrease in mucosa layer thickness down 
to 85.57 % ± 1.9 compared to untreated control (p<0.0001). Simultaneous incubation of 
ethanolic myrrh extract (MY, 0.15 mg/ml) led to a comparable decrease of mucosa layer 
thickness (Figure 34; 0.15 mg/ml MY: 84.16 % ± 7.3, p<0.001). 
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Effect of ethanolic myrrh extract on TNBS-induced contractility decrease 
 
Figure 35: Effect of ethanolic myrrh extract on TNBS-induced contractility decrease 
(A: representative original recording; B: statistical analysis). 
Rat ileum/jejunum preparations were incubated with TNBS (10 mM) and ethanolic myrrh extract (MY; 
0.1 – 1 mg/ml) for 30 minutes and ACh-induced contractions were determined. TNBS-incubation alone 
served as positive control. Presented is a representative original recording (A) and statistical analysis 
(B) with mean ± SEM (n = 12); the vertical line in (A) represents basal tone; * p<0.01 vs. untreated 
control, # p<0.05 vs. TNBS. 
In this series of experiments incubation with TNBS (10 mM; 30 minutes) induced a decrease 
in ACh-induced contraction down to 71.99 % ± 3.6 compared to untreated control (p<0.01). 
Simultaneous incubation of ethanolic myrrh extract in a concentration of 0.1 mg/ml did not 
significantly alter ACh-induced contractions compared to control (Figure 35; 0.1 µg/ml MY: 
86.38 % ± 11.35). However, 1.0 mg/ml ethanolic myrrh extract led to a further decrease in 
ACh-induced contraction compared to single TNBS-treatment (Figure 35; 1.0 µg/ml MY: 
53.48 % ± 4.6, p<0.05 vs. TNBS). 
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Effect of aqueous myrrh extract on TNBS-induced contractility decrease 
 
Figure 36: Effect of aqueous myrrh extract on TNBS-induced contractility decrease 
(A: representative original recording; B: statistical analysis). 
Rat ileum/jejunum preparations were incubated with TNBS (10 mM) and aqueous myrrh extract (MYA; 
0.1 – 1 mg/ml) for 30 minutes and ACh-induced contractions were determined. TNBS-incubation alone 
served as positive control. Presented is a representative original recording (A) and statistical analysis 
(B) with mean ± SEM; the vertical line in (A) represents basal tone; n = 12. 
The influence of aqueous myrrh extract on TNBS-induced contractility decrease is presented 
in Figure 36. Incubation with TNBS (10 mM; 30 minutes) induced a decrease in ACh-induced 
contraction down to 70.95 % ± 3.6 compared to untreated control (p<0.001). Simultaneous 
incubation of aqueous myrrh extract in a concentration of 1 – 100 mg/ml did not significantly 
alter ACh-induced contractility compared to control (Figure 36; 1 mg/ml MYA: 71.84±2.9; 
10 mg/ml MYA: 68.06±5.4; 100 mg/ml MYA: 80.03±3.6, in % control). However, the lowest 
concentration of aqueous myrrh extract tested, inhibited the TNBS-induced reduction of 
ACh-induced contraction (Figure 36; 0.1 mg/ml MYA: 114.8±5.7, p<0.001 vs. TNBS). 
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Effect of ethanolic myrrh extract on TNBS-induced TNFα gene expression 
The influence of ethanolic myrrh extract on TNBS-induced overexpression of TNFα-mRNA in 
rat small intestinal preparations is presented in Figure 37. 
 
Figure 37: Effect of ethanolic myrrh extract on TNBS-induced TNFα gene expression 
Rat ileum/jejunum preparations were incubated with TNBS (10 mM) and ethanolic myrrh extract (MY; 
0.1 - 100 mg/ml) for 3 hours and the amount of TNFα-mRNA expression was analysed using real time 
PCR. TNBS-incubation alone served as positive control. Presented are mean ± SEM (n = 4) of TNFα-
mRNA expression in relation to untreated control; * p<0.01 vs. untreated control. 
Incubation with TNBS (10 mM; 3 hours) induced a 4-fold increase in TNFα-mRNA expression 
compared to untreated control (p<0.01). Simultaneous incubation of TNBS and ethanolic myrrh 
extract (0.001 – 1 mg/ml) resulted in mRNA-expression levels below that induced by TNBS, 
however no statistically significant reduction in TNFα-mRNA expression compared to TNBS 
effect could be observed. (Figure 37; 0.001 mg/ml MY: 0.87±0.1; 0.01 mg/ml MY: 1.43±0.5; 
0.1 mg/ml MY: 1.36±0.3; 1 mg/ml MY: 0.85±0.3; -fold compared to untreated control). 
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Effect of aqueous myrrh extract on TNBS-induced TNFα gene expression 
The influence of aqueous myrrh extract on TNBS-induced overexpression of TNFα-mRNA in 
rat small intestinal preparations is presented in Figure 38. 
 
Figure 38: Effect of aqueous myrrh extract on TNBS-induced TNFα gene expression 
Rat ileum/jejunum preparations were incubated with TNBS (10 mM) and aqueous myrrh extract (MY; 
0.1 - 100 mg/ml) for 3 hours and the amount of TNFα-mRNA expression was analysed using real time 
PCR. TNBS-incubation alone served as positive control. Presented are mean ± SEM (n = 4) of TNFα-
mRNA expression in relation to untreated control; * p<0.01 vs. untreated control, # p<0.05 vs. TNBS. 
Incubation with TNBS (10 mM; 3 hours) induced a 4-fold increase in TNFα-mRNA expression 
compared to untreated control (p<0.01). Simultaneous incubation of TNBS and aqueous myrrh 
extract (MYA, 0.1 – 100 mg/ml) led to a significant inhibition of the TNFα-mRNA expression 
(Figure 38; 0.1 mg/ml MYA: 1.16±0.7; 1.0 mg/ml MYA: 0.72±0.4, p<0.05; 10 mg/ml MYA: 
0.62±0.2, p<0.05; 100 mg/ml MYA: 0.92±0.4; -fold compared to untreated control). 
Effect of ethanolic myrrh extract on LPS-induced TNFα release 
To determine the influence of ethanolic myrrh extract on LPS-induced TNFα release, LPS-
stimulated (100 ng/ml), differentiated THP-1cells were incubated with ethanolic myrrh extract 
(MY, 0.1 – 200 µg/ml) for four hours. Subsequently, TNFα amount in cell supernatant was 
determined by ELISA. Differentiated THP-1 cells without LPS stimulation (u.c.), differentiated 
cells that were solely stimulated with LPS (LPS; 100 ng/ml) and differentiated cells that were 
treated with LPS and the anti-inflammatory glucocorticoid budesonide (Bud; 1 nM) were 
additionally tested as controls. TNFα release of LPS-stimulated THP-1 cells was set 100 %. 
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Figure 39: Effect of ethanolic myrrh extract on LPS-induced TNFα release from THP-1 cells. 
Differentiated THP-1 cells were treated with LPS (100 ng/ml) and ethanolic myrrh extract (MY; 0.1 – 
200 µg/ml) and incubated for four hours. TNFα release was determined by ELISA. Budesonide (Bud, 
1 nM) served as positive control. Data are presented as mean ± SEM; * p<0.05 vs. untreated control 
(u.c.), # p<0.001 vs. LPS, n = 8-10. 
The influence of ethanolic myrrh extract (MY, 0.1 – 200 µg/ml) on LPS-induced TNFα release 
from THP-1 cells is presented in Figure 39. LPS (100 ng/ml) significantly increased TNFα 
release in differentiated THP-1 cells (Figure 39; u.c.: 8.73 % ± 1.4; LPS: 100 %, p<0.0001). 
After simultaneous treatment with budesonide (1 nM), TNFα release was significantly 
decreased compared to single LPS stimulation (Figure 39; LPS: 100 %, Bud: 15.15 % ± 3.2; 
p<0.0001). DMSO in applied concentrations had no influence on TNFα release. 
Ethanolic myrrh extract led to a concentration-dependent decrease in TNFα release down to 
2 % ± 0.3 (Figure 39; 0.1 µg/ml MY: 99.76±8.8; 1.0 µg/ml MY: 95.3±7.0; 5.0 µg/ml MY: 
99.03±1.5; 10.0 µg/ml MY: 87.79±4.4; 20 µg/ml MY: 88.69±2.6; 50 µg/ml MY: 60.69±3.9, 
p<0.0001; 100 µg/ml MY: 28.57±7.4, p<0.0001; 200 µg/ml MY: 2.45±0.3, p<0.0001; in % LPS-
treatment). 
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Figure 40: Effect of ethanolic myrrh extract on metabolic activity (A) and LDH-release (B) of 
THP-1 cells. 
Differentiated THP-1 cells were treated with LPS (100 ng/ml) and ethanolic myrrh extract (MY; 0.1 – 
200 µg/ml) and incubated for four hours. Metabolic activity was determined by MTT-assay; LDH-assay 
was performed to determine LDH-release. Data are presented as mean ± SEM (n = 8-10); *** p<0.001 
vs. untreated control (u.c.). 
To evaluate the viability of the cells used for determination of TNFα release, MTT-assay and 
LDH-assay were performed after treatment with the respective substances (Figure 40). 
Cell viability expressed as metabolic activity of differentiated THP-1 cells was not influenced 
after simultaneous incubation with LPS (100 ng/ml) and budesonide (1 nM). Increasing 
concentrations of ethanolic myrrh extract did not alter cell viability in a concentration range of 
0.1 – 100 µg/ml compared to untreated control. However, the highest concentration decreased 
metabolic activity to 48.25 % ± 2.2 (p<0.001) compared to untreated control. 
LDH-release was not influenced by treatment with LPS (100 ng/ml) or simultaneous treatment 
with budesonide (1 nM) or ethanolic myrrh extract (0.1 – 1000 µg/ml).  
To realise a distinction between the inhibition of TNFα release and influence of metabolic 
activity, a selectivity index was determined. Therefore, the concentration-response curves for 
TNFα release and metabolic activity were evaluated and half maximal inhibitory concentrations 
(IC50) were calculated (Figure 41). 
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Figure 41: Concentration-response curves of ethanolic myrrh extract on LPS-induced TNFα 
release and metabolic activity 
To determine the selectivity index the concentration-response curves and IC50-values, for TNFα 
release (IC50 B) and metabolic activity (IC50 A) were ascertained by non-linear regression. Data are 
presented as mean ± SEM (n = 8-10) and non-linear regression curves for TNFα release (▲) and 
metabolic activity (■). 
Ethanolic myrrh extract reduced the TNFα release with an IC50-value of 60.65 µg/ml and the 
metabolic activity with an IC50-value of 353.7 µg/ml. The resulting selectivity index (SI = 5.8) 
indicates that reduction of metabolic activity occurs in 6-fold higher concentrations compared 
to reduction of TNFα release. 
Effect of aqueous myrrh extract on LPS-induced TNFα release 
 
Figure 42: Effect of aqueous myrrh extract on LPS-induced TNFα release from THP-1 cells. 
Differentiated THP-1 cells were treated with LPS (100 ng/ml) and aqueous myrrh extract (MYA; 0.1 – 
1000 µg/ml) and incubated for four hours. TNFα release was determined by ELISA. Budesonide (Bud, 
1 nM) served as positive control. Data are presented as mean ± SEM; * p<0.05 vs. untreated control 
(u.c.), # # # p<0.001 vs. LPS, # p<0.05 vs. LPS; n = 8-10. 
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LPS (100 ng/ml) significantly increased TNFα release in differentiated THP-1 cells (Figure 42; 
u.c.: 8.73 % ± 1.4; LPS: 100 %, p<0.0001). After simultaneous treatment with budesonide 
(1 nM) TNFα release was significantly decreased compared to single LPS stimulation (Figure 
42; LPS: 100 %, Bud: 15.15 % ± 3.2; p<0.0001).  
Aqueous myrrh extract in concentrations up to 100 µg/ml did not influence TNFα release 
compared to sole LPS stimulation. However, in the highest concentration tested it significantly 
decreased LPS-induced TNFα release to a comparably small extent (Figure 42; 0.1 mg/ml 
MYA: 97.98±1.5; 1 µg/ml MYA: 98.92±2.7; 10 µg/ml MYA: 97.85±1.4; 100 µg/ml MYA: 
93.68±2.6; 1000 µg/ml MYA: 89.24±2.5, p<0.05; in % LPS-treatment). 
To evaluate the viability of the cells used for determination of TNFα release, MTT-assay and 
LDH-assay were performed after treatment with the respective substances (Figure 43). 
 
Figure 43: Effect of aqueous myrrh extract on metabolic activity (A) and LDH-release (B) of 
THP-1 cells. 
Differentiated THP-1 cells were treated with LPS (100 ng/ml) and aqueous myrrh extract (MYA; 0.1 – 
1000 µg/ml) and incubated for four hours. Metabolic activity was determined by MTT-assay; LDH-
assay was performed to determine LDH-release. Data are presented as mean ± SEM; n = 8-10. 
Cell viability expressed as metabolic activity of differentiated THP-1 cells was not influenced 
after simultaneous incubation with LPS (100 ng/ml) and budesonide (1 nM).  
Aqueous myrrh extract in the concentrations tested did not influence metabolic activity of the 
cells.  
Treatment with LPS (100 ng/ml) or simultaneous treatment with budesonide (1 nM) or aqueous 
myrrh extract (0.1 – 1000 µg/ml) did not alter LDH-release compared to untreated control. 
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Effect of aqueous myrrh extract on basal TNFα release 
 
 
Figure 44: Effect of aqueous myrrh extract on basal TNFα release from THP-1 cells. 
Differentiated THP-1 cells were treated with aqueous myrrh extract (MYA; 0.1 – 1000 µg/ml) and 
incubated for four hours. Budesonide (Bud, 1 nM) served as positive control. TNFα release was 
determined by ELISA. Data are presented as mean ± SEM; * p<0.0001 vs. untreated control (u.c.); 
n = 8. 
To determine the effect of aqueous myrrh extract on basal TNFα release, differentiated THP-
1 cells were incubated with aqueous myrrh extract (MYA, 0.1 – 1000 µg/ml) for four hours and 
TNFα in the cell supernatant was quantified. LPS as positive control induced a TNFα release 
of 1712 % ± 315 compared to untreated control. Aqueous myrrh extract in concentrations up 
to 100 µg/ml did not influence basal TNFα release compared to untreated control. However, 
the highest concentration led to an increase in TNFα release (Figure 44; 0.1 µg/ml MYA: 
101.1±5.1; 1.0 µg/ml MYA: 100.9±4.0; 10 µg/ml MYA: 117.4±7.9; 100 µg/ml MYA: 
201.2±47.35; 1000 µg/ml MYA: 774.8±294.7, p<0.0001; in % untreated control). 
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Effect of ethanolic myrrh extract on LPS-induced NO release 
The following experiments were kindly allowed to be performed at the Institute of 
Pharmaceutical Biology and Phytochemistry, University of Münster, in the laboratories of 
Prof. A. Hensel. 
 
Figure 45: Effect of ethanolic myrrh extract on LPS-induced nitric oxide (NO) release from RAW 
264.7 cells 
RAW 264.7 macrophages were treated with LPS (100 ng/ml) and ethanolic myrrh extract (MY; 0.1 – 
1000 µg/ml) and incubated for 24 hours. NO release was determined colorimetrically by Griess 
reaction. Aminoguanidine (AG, 1 nM) served as positive control. Presented are statistical analysis [A] 
and concentration-response curve [B]. Data are presented as mean ± SEM and non-linear regression; 
* p<0.05 vs. untreated control (u.c.); # p<0.001 vs. LPS; n = 6. 
LPS (100 ng/ml) significantly increased NO release from RAW 264.7 macrophages (Figure 45; 
u.c.: 10.93 % ± 1.3; LPS: 100 %, p<0.001). After simultaneous treatment with the inducible 
nitric oxide synthase inhibitor aminoguanidine (1 nM), NO release was significantly decreased 
compared to single LPS stimulation (Figure 45; LPS: 100 %, aminoguanidine: 61.15 % ± 3.2; 
p<0.001). DMSO in applied concentrations had no influence on NO release.  
Ethanolic myrrh extract led to a concentration-dependent decrease in NO release down to 
11 % ± 1.0 with a half maximal inhibitory concentration (IC50) of 24.24 µg/ml (Figure 45; 
0.001 µg/ml MY: 100.7±2.1; 0.01 µg/ml MY: 102.5±2.0; 0.1 µg/ml MY: 97.87±2.6; 1 µg/ml MY: 
97.42±1.8; 10 µg/ml MY: 76.58±4.8, p<0.001; 100 µg/ml MY: 10.69±1.0, p<0.001; in % LPS-
treatment). 
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Effect of aqueous myrrh extract on LPS-induced NO release 
 
Figure 46: Effect of aqueous myrrh extract on LPS-induced nitric oxide (NO) release from RAW 
264.7 cells 
RAW 264.7 macrophages were treated with LPS (100 ng/ml) and aqueous myrrh extract (MYA; 0.1 – 
1000 µg/ml) and incubated for 24 hours. NO release was determined colorimetrically by Griess 
reaction. Aminoguanidine (AG, 1 nM) served as positive control. Presented are statistical analysis [A] 
and concentration-response curve [B]. Data are presented as mean ± SEM and non-linear regression; 
* p<0.05 vs. untreated control (u.c.); # p<0.001 vs. LPS; n = 6. 
LPS (100 ng/ml) significantly increased NO release from RAW 264.7 macrophages (Figure 46; 
u.c.: 10.93 % ± 1.3; LPS: 100 %, p<0.001). After simultaneous treatment with the inducible 
nitric oxide synthase inhibitor aminoguanidine (1 nM), NO release was significantly decreased 
compared to single LPS stimulation (Figure 46; LPS: 100 %, aminoguanidine: 61.15 % ± 3.2; 
p<0.001). 
Aqueous myrrh extract in concentrations up to 100 µg/ml did not influence LPS-stimulated NO 
release. However, the highest concentration induced a decrease of released NO (Figure 46; 
0.01 µg/ml MYA: 96.65±3.3; 0.1 µg/ml MYA: 98.46±1.2; 1 µg/ml MYA: 100.2±2.0; 10 µg/ml 
MYA: 95.68±2.6; 10 µg/ml: 95.48±2.6; 100 µg/ml: 91.61±2.6; 1000 µg/ml MYA: 53.98±6.0, 
p<0.001 in % untreated control; IC50: 858.0 µg/ml). 
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Effect of aqueous myrrh extract on basal NO release 
To determine the effect of aqueous myrrh extract on basal NO release, RAW 264.7 cells were 
incubated with aqueous myrrh extract (MYA; 0.01 – 1000 µg/ml) for 48 hours and NO release 
was quantified colorimetrically by Griess reaction. 
 
Figure 47: Effect of aqueous myrrh extract on basal NO release from RAW 264.7 cells. 
RAW 264.7 cells were treated with aqueous myrrh extract (MYA; 0.01 – 1000 µg/ml) and incubated for 
48 hours. NO release was determined colorimetrically by Griess reaction. Data are presented as 
mean ± SEM; * p<0.0001 vs. untreated control (u.c.); n = 4. 
LPS as positive control induced a NO release of 1369 % ± 64 compared to untreated control. 
Aqueous myrrh extract in concentrations up to 100 µg/ml did not influence basal NO release 
compared to untreated control. However, the highest concentration led to an increase in NO 
release (Figure 47; 0.01 µg/ml MYA: 117.6±5.4; 0.1 mg/ml MYA: 116.6±3.0; 1 µg/ml MYA: 
107.7±2.7; 10 µg/ml MYA: 118.4±4.7; 100 mg/ml MYA: 143.5±15.7; 1000 µg/ml MYA: 
417.7±76.05, p<0.0001; in % untreated control). 
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3.2.3 Anti-inflammatory activity of coffee charcoal 
Effect of coffee charcoal extract on TNBS-induced morphological damage 
 
Figure 48: Effect of coffee charcoal extract on TNBS-induced morphological damage. 
Rat ileum preparations were incubated with TNBS (100 mM) and coffee charcoal extract (CC; 3 
mg/ml) for 30 minutes and mucosa layer thickness was determined morphometrically after HE-
staining. Single TNBS-incubation served as positive control. Presented are representative original 
images (A-C) and statistical analysis (D) with mean ± SEM; * p<0.05 vs. untreated control (u.c.); n = 4. 
Incubation with TNBS (100 mM; 30 minutes) induced a morphological damage expressed by 
a decrease in mucosa layer thickness down to 89.27 % ± 3.9 compared to untreated control 
(p<0.05). Simultaneous incubation of coffee charcoal extract (CC, 3 mg/ml) did not decrease 
mucosa layer thickness compared to untreated control (Figure 48; 3 mg/ml CC: 97.65 % ± 2.0; 
in % untreated control). However, the difference in mucosa layer thickness after single TNBS 
treatment and simultaneous incubation with coffee charcoal extract (3 mg/ml) was not 
statistically significant. 
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Effect of coffee charcoal extract on TNBS-induced contractility decrease 
 
Figure 49: Effect of coffee charcoal extract on TNBS-induced contractility decrease 
(A: representative original recording; B: statistical analysis). 
Rat ileum/jejunum preparations were incubated with TNBS (10 mM) and coffee charcoal extract (CC; 
17.8 and 89.4 mg/ml) for 30 minutes and ACh-induced contractions were determined using isometric 
tension measurement. Single TNBS-incubation served as positive control. Presented is a 
representative original recording (A) and statistical analysis (B) with mean ± SEM; * p<0.0001 vs. 
untreated control (u.c.); n = 6. 
Incubation with TNBS (10 mM; 30 minutes) induced a decrease in ACh-induced contraction 
down to 70.95 % ± 3.4 compared to untreated control (p<0.0001). Simultaneous incubation of 
coffee charcoal extract (CC; 18 and 90 µg/ml) induced a similar effect (Figure 49; 18 µg/ml 
CC: 70.55±5.5; 90 µg/ml CC: 73.56±3.7; in % untreated control) and had therefore, no effect 
on TNBS-induced contractility decrease. 
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Effect of coffee charcoal extract on TNBS-induced TNFα gene expression 
The influence of coffee charcoal extract on TNBS-induced overexpression of TNFα-mRNA in 
rat small intestinal preparations is presented in Figure 50. 
 
Figure 50: Effect of coffee charcoal extract on TNBS-induced TNFα gene expression 
Rat ileum/jejunum preparations were incubated with TNBS (10 mM) and coffee charcoal extract (CC; 
0.1 - 100 mg/ml) for 3 hours and the amount of TNFα-mRNA expression was analysed using real time 
PCR. TNBS-incubation alone served as positive control. Presented are mean ± SEM (n = 5) of TNFα-
mRNA expression in relation to untreated control; * p<0.01 vs. untreated control. 
Incubation with TNBS (10 mM; 3 hours) induced a 4-fold increase in TNFα-mRNA expression 
compared to untreated control (p<0.01). Simultaneous incubation of TNBS and coffee charcoal 
extract (0.1 – 100 mg/ml) did not influence the mRNA-expression levels of TNFα compared to 
sole TNBS-stimulation. 
Effect of coffee charcoal extract on LPS-induced TNFα release 
To determine the influence of coffee charcoal extract on LPS-induced TNFα release, LPS-
stimulated (100 ng/ml), differentiated THP-1cells were incubated with coffee charcoal extract 
(CC, 0.1 – 1500 µg/ml) for four hours. Subsequently, TNFα amount in cell supernatant was 
determined by ELISA. Differentiated THP-1 cells without LPS stimulation (u.c.) differentiated 
cells that were solely stimulated with LPS (LPS; 100 ng/ml) and differentiated cells that were 
treated with LPS and the anti-inflammatory glucocorticoid budesonide (Bud; 1 nM) were 
additionally tested as controls. TNFα release of LPS-stimulated THP-1 cells was set 100 %. 
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Figure 51: Effect of coffee charcoal extract on LPS-induced TNFα release from THP-1 cells. 
Differentiated THP-1 cells were treated with LPS (100 ng/ml) and coffee charcoal extract (CC; 0.1 – 
1500 µg/ml) and incubated for four hours. Budesonide (Bud, 1 nM) served as positive control. 
Presented are statistical analysis [A] and concentration-response curve [B]. Data are presented as 
mean ± SEM and non-linear regression; * p<0.05 vs. untreated control (u.c.); # p<0.05 vs. LPS, 
# # p<0.01 vs. LPS, # # # p<0.001 vs. LPS; n = 8-10. 
The influence of coffee charcoal extract (CC, 0.1 – 1000 µg/ml) on LPS-induced TNFα release 
from THP-1 cells is presented in Figure 51. LPS (100 ng/ml) significantly increased TNFα 
release in differentiated THP-1 cells (Figure 51; u.c.: 4.35 % ± 1.3; LPS: 100 %, p<0.0001). 
After simultaneous treatment with budesonide (1 nM) TNFα release was significantly 
decreased compared to single LPS stimulation (Figure 51; LPS: 100 %, Bud: 12.5 % ± 1.7; 
p<0.0001). 
Coffee charcoal extract led to a concentration-dependent decrease in TNFα release down to 
28 % ± 8.7 with a half maximal inhibitory concentration (IC50) of 1886 µg/ml (Figure 51; 0.1 
µg/ml CC: 93.82±5.0; 1.0 µg/ml CC: 100.7±2.4; 10 µg/ml CC: 102.7±3.6; 50 µg/ml CC: 
98.19±3.2; 100 µg/ml CC: 90.76±2.6, p<0.05; 500 µg/ml 84.77±3.5, p<0.01; 1000 µg/ml 
CC: 63.15±4.4, p<0.0001; 1500 µg/ml CC: 56.03±3.8, p<0.0001; in % LPS-treatment). 
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To evaluate the viability of the cells used for determination of TNFα release, MTT-assay and 
LDH-assay were performed after treatment with the respective substances (Figure 52). 
 
Figure 52: Effect of coffee charcoal extract on metabolic activity (A) and LDH-release (B) of 
THP-1 cells. 
Differentiated THP-1 cells were treated with LPS (100 ng/ml) and coffee charcoal extract (CC; 0.1 – 
1500 µg/ml) and incubated for four hours. Metabolic activity was determined by MTT-assay; LDH-
assay was performed to determine LDH-release. Untreated control (u.c.); LPS and budesonide (Bud 
1 nM) were tested as controls. Data are presented as mean ± SEM (n = 8-10). 
Cell viability expressed as metabolic activity of differentiated THP-1 cells was not influenced 
after simultaneous incubation with LPS (100 ng/ml) and budesonide (1 nM) or coffee charcoal 
extract in the concentrations tested. Treatment with LPS (100 ng/ml) or simultaneous treatment 
with budesonide (1 nM) or coffee charcoal extract (0.1–1500 µg/ml) did not alter LDH-release 
compared to untreated control. 
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3.3 Microarray gene expression analysis 
To investigate the influence of all plant extracts on gene expression profile of human M1-
macrophages, LPS/IFNγ-stimulated cells were incubated with the plant extract in selected 
concentrations. After isolation of the total RNA, gene expression analysis was performed at 
the Core Unit DNA Technologies of the Interdisciplinary Centre for Clinical Research (IZKF, 
Medical Faculty, University of Leipzig) using a HumanHT-12 v4 Expression BeadChip.  
3.3.1 Effect of LPS/IFNγ-stimulation on gene expression profile of human M1-
macrophages 
Microarray gene expression analysis was performed to assess alterations in gene expression 
profile of human M1-macrophages. LPS (100 ng/ml) and IFNγ (10 ng/ml) were used as 
inflammatory stimulus to activate the macrophages.  
Table 25 and Table 26 present an overview of the number of genes that were affected by the 
LPS/IFNγ-stimulation. 
Table 25: Influence of LPS/IFNγ-stimulation on number of regulated genes compared to untreated 
control (u.c.) (data from first gene expression analysis procedure, 20/03/2014). 
Signal LPS/IFNγ / 
Signal u.c. 
Number of 
regulated genes 
> 1000 2 
> 100 35 
> 10 640 
< 0.1 812 
< 0.01 25 
< 0.001 0 
 
Table 26: Influence of LPS/IFNγ-stimulation on number of regulated genes compared to untreated 
control (u.c.) (data from second gene expression analysis procedure, 17/04/2014). 
Signal LPS/IFNγ / 
Signal u.c. 
Number of 
regulated genes 
> 1000 9 
> 100 50 
> 10 548 
< 0.1 431 
< 0.01 19 
< 0.001 0 
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All genes that were up-regulated more than 10-fold were analysed by enrichment analysis. 
Figure 53 - 54 show a visualisation of the gene ontological enrichment analysis. 
 
Figure 53: Gene ontological enrichment analysis of gene up-regulation after LPS/IFNγ-
stimulation (data from first gene expression analysis procedure, 20/03/2014). 
Enrichment analysis of genes that were up-regulated after LPS/IFNγ-stimulation (regulation-
factor ≥ 10; total: 640 genes). Analysis was performed using WEB-based GEne SeT AnaLysis Toolkit 
(WebGestalt software, version 1/30/2013). Presented are categories including two or more genes; 
hypergeometric test with Multiple Test Adjustment BH; categories with the ten lowest significance 
levels (adjusted p-values, adjP) are highlighted in grey. 
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Figure 54: Gene ontological enrichment analysis of gene up-regulation after LPS/IFNγ-
stimulation (data from second gene expression analysis procedure, 17/04/2014). 
Enrichment analysis of genes that were up-regulated after LPS/IFNγ-stimulation 
(regulation-factor ≥ 10; total: 548 genes). Analysis was performed using WEB-based GEne SeT 
AnaLysis Toolkit (WebGestalt software, version 1/30/2013). Presented are categories including two or 
more genes; hypergeometric test with Multiple Test Adjustment BH; categories with the ten lowest 
significance levels (adjusted p-values) are highlighted in grey. 
Genes that were up-regulated after LPS/IFNγ-stimulation can be classified in GO-categories 
that are associated with the adaptive immune system like chemokine activity, chemoattractant 
activity, chemokine activity and the kynurenine pathway of tryptophan metabolism including 
indoleamine 2,3-dioxygenase activity and tryptophan 2,3-dioxygenase activity. 
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All genes that were down-regulated more than 10-fold were likewise analysed by enrichment 
analysis. Figure 55 - 56 show a visualisation of the gene ontological enrichment analysis. 
 
 
Figure 55: Gene ontological enrichment analysis of gene down-regulation after LPS/IFNγ-
stimulation (data from first gene expression analysis procedure, 20/03/2014). 
Enrichment analysis of genes that were down-regulated after LPS/IFNγ-stimulation 
(regulation-factor ≤ 0.1; total: 812 genes). Analysis was performed using WEB-based GEne SeT 
AnaLysis Toolkit (WebGestalt software, version 1/30/2013). Presented are categories including two or 
more genes; hypergeometric test with Multiple Test Adjustment BH; categories with the ten lowest 
significance levels (adjusted p-values) are highlighted in grey. 
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Figure 56: Gene ontological enrichment analysis of gene down-regulation after LPS/IFNγ-
stimulation (data from second gene expression analysis procedure, 17/04/2014). 
Enrichment analysis of genes that were down-regulated after LPS/IFNγ-stimulation 
(regulation-factor ≤ 0.1; total: 431 genes). Analysis was performed using WEB-based GEne SeT 
AnaLysis Toolkit (WebGestalt software, version 1/30/2013). Presented are categories including two or 
more genes; hypergeometric test with Multiple Test Adjustment BH; categories with the ten lowest 
significance levels (adjusted p-values) are highlighted in grey. 
GO-categories that were significantly enriched after LPS/IFNγ-stimulation include biological 
processes associated with cell cycle regulation including cell cycle division and mitosis. 
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3.3.2 Effect of chamomile flower extract on LPS/IFNγ-induced change in gene 
expression profile of human M1-macrophages 
To assess the influence of chamomile flower on LPS/IFNγ-induced changes in gene 
expression of human M1-macrophages, cells were treated simultaneously with chamomile 
flower extract (200 mg/ml) and LPS/IFNγ. Single treatment with LPS/IFNγ and untreated cells 
served as control. 
Table 27 presents an overview of the number of genes that were affected by the treatment 
with chamomile flower extract compared to LPS/IFNγ-stimulation. 
Table 27: Influence of chamomile flower extract (KA) on number of regulated genes compared to 
LPS/IFNγ-stimulation (data from second gene expression analysis procedure, 17/04/2014). 
 
Signal KA / 
Signal LPS/IFNγ 
Number of 
regulated genes 
> 1000 0 
> 100 0 
> 10 78 
< 0.1 104 
< 0.01 0 
< 0.001 0 
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Figure 57: Gene ontological enrichment analysis – Influence of chamomile flower extract 
(200 mg/ml) on LPS/IFNγ-stimulated gene expression (data from second gene expression 
analysis procedure, 17/04/2014). 
Enrichment analysis of genes that were down-regulated after simultaneous treatment with LPS/IFNγ 
and chamomile flower extract (200 µg/ml) compared to single LPS/IFNγ-stimulation (regulation-factor 
≤ 0.1 vs. LPS/IFNγ-stimulation; total: 104 genes). Analysis was performed using WEB-based GEne 
SeT AnaLysis Toolkit (WebGestalt software, version 1/30/2013). Presented are categories including 
two or more genes; hypergeometric test with Multiple Test Adjustment BH; categories with the ten 
lowest significance levels (adjusted p-values) are highlighted in grey. 
Figure 57 presents a visualisation of the gene ontological enrichment analysis. CXCR 
chemokine receptor binding1 was the only category that shows a significant enrichment with 
genes down-regulated more than 10-fold compared to LPS/IFNγ-stimulation. 
 
Genes that were up-regulated after simultaneous treatment with chamomile flower extract 
compared to LPS/IFNγ-stimulation could not be clustered significantly in GO-categories 
(adjP ≥ 0.05) (data not presented). 
  
                                                     
1 genes concerned: CXCL12 - chemokine (C-X-C Motif) ligand 12; CXCL 13 - chemokine (C-X-C 
Motif) ligand 13 
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3.3.3 Effect of myrrh on LPS/IFNγ-induced change in gene expression profile of 
human M1-macrophages 
The influence of ethanolic and aqueous myrrh extract on LPS/IFNγ-induced changes in gene 
expression of human M1-macrophages was assessed after simultaneous treatment with 
ethanolic (30 mg/ml) or aqueous (500 µg/ml) myrrh extract and LPS/IFNγ. Single treatment 
with LPS/IFNγ and untreated cells served as control. 
Effect of ethanolic myrrh extract on LPS/IFNγ-induced change in gene expression profile of 
human M1-macrophages 
Table 28 presents an overview of the number of genes that were affected by the treatment 
with ethanolic myrrh extract compared to LPS/IFNγ-stimulation. 
Table 28: Influence of ethanolic myrrh extract (MY) on number of regulated genes compared to 
LPS/IFNγ-stimulation (data from first gene expression analysis procedure, 20/03/2014). 
Signal MY / 
Signal LPS/IFNγ 
Number of 
regulated genes 
> 1000 0 
> 100 0 
> 10 84 
< 0.1 202 
< 0.01 0 
< 0.001 0 
 
Figure 58 presents a visualisation of the gene ontological enrichment analysis.  
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Figure 58: Gene ontological enrichment analysis – Influence of ethanolic myrrh extract 
(30 mg/ml) on LPS/IFNγ-stimulated gene expression (data from first gene expression analysis 
procedure, 20/03/2014). 
Enrichment analysis of genes that were up-regulated after simultaneous treatment with LPS/IFNγ and 
ethanolic myrrh extract (30 mg/ml) compared to single LPS/IFNγ-stimulation (regulation-factor ≥ 10 vs. 
LPS/IFNγ-stimulation; total: 84 genes). Analysis was performed using WEB-based GEne SeT 
AnaLysis Toolkit (WebGestalt software, version 1/30/2013). Presented are categories including two or 
more genes; hypergeometric test with Multiple Test Adjustment BH; categories with the ten lowest 
significance levels (adjusted p-values) are highlighted in grey. 
Genes that were up-regulated more than 10-fold compared to LPS/IFNγ-stimulation can be 
clustered in categories with a significant enrichment, including retinol dehydrogenase activity2, 
monooxygenase activity3 and oxidoreductase activity4. 
Genes that were down-regulated after simultaneous treatment with ethanolic myrrh extract 
compared to LPS/IFNγ-stimulation could not be clustered in significantly enriched GO-
categories (adjP ≥ 0.05) (data not presented). 
                                                     
2 genes concerned: SDR9C7 - short chain dehydrogenase/reductase family 9C, member 7; AKR1C3 - 
aldo-keto reductase family 1, member C3 
3 genes concerned: CYP2U1 - cytochrome P450, family 2, subfamily U, polypeptide 1; AKR1C3 - aldo-
keto reductase family 1, member C3; CYP4F3 - cytochrome P450, family 4, subfamily F, polypeptide 3 
4 genes concerned: AKR1C3 - aldo-keto reductase family 1, member C3; CYP4F3 - cytochrome P450, 
family 4, subfamily F, polypeptide 3 
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Effect of aqueous myrrh extract on LPS/IFNγ-induced change in gene expression profile of 
human M1-macrophages 
Table 29 presents an overview of the number of genes that were affected by the treatment 
with aqueous myrrh extract compared to LPS/IFNγ-stimulation. 
Table 29: Influence of aqueous myrrh extract (MYA) on number of regulated genes compared to 
LPS/IFNγ-stimulation (data from second gene expression analysis procedure, 17/04/2014). 
Signal MYA / 
Signal LPS/IFNγ 
Number of 
regulated genes 
> 1000 0 
> 100 0 
> 10 25 
< 0.1 112 
< 0.01 0 
< 0.001 0 
Genes that were up- or down-regulated after simultaneous treatment with aqueous myrrh 
extract compared to LPS/IFNγ-stimulation by the factor 10 could not be clustered in 
significantly enriched GO-categories (adjP ≥ 0.05) (data not presented). 
3.3.4 Effect of coffee charcoal extract on LPS/IFNγ-induced change in gene 
expression profile of human M1-macrophages 
The influence of coffee charcoal extract on LPS/IFNγ-induced changes in gene expression of 
human M1-macrophages was assessed after simultaneous treatment with coffee charcoal 
extract and LPS/IFNγ. Single treatment with LPS/IFNγ and untreated cells served as control. 
Table 30: Influence of coffee charcoal extract (CC) on number of regulated genes compared to 
LPS/IFNγ-stimulation (data from first gene expression analysis procedure, 20/03/2014). 
Signal CC / 
Signal LPS/IFNγ 
Number of 
regulated genes 
> 1000 1 
> 100 5 
> 10 195 
< 0.1 372 
< 0.01 6 
< 0.001 0 
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Figure 59 - 60 present a visualisation of the gene ontological enrichment analysis.  
 
Figure 59: Gene ontological enrichment analysis – Influence of coffee charcoal extract 
(500 mg/ml) on LPS/IFNγ-stimulated gene expression (data from second gene expression 
analysis procedure, 20/03/2014). 
Enrichment analysis of genes that were down-regulated after simultaneous treatment with LPS/IFNγ 
and charcoal extract (500 mg/ml) compared to single LPS/IFNγ-stimulation (regulation-factor ≤ 0.1 vs. 
LPS/IFNγ-stimulation; total: 372 genes). Analysis was performed using WEB-based GEne SeT 
AnaLysis Toolkit (WebGestalt software, version 1/30/2013). Presented are categories including two or 
more genes; hypergeometric test with Multiple Test Adjustment BH; categories with the ten lowest 
significance levels (adjusted p-values) are highlighted in grey. 
Genes that were down-regulated more than 10-fold compared to LPS/IFNγ-stimulation can be 
clustered in significantly enriched categories associated with chemokine signalling including 
chemokine activity, CXCR chemokine receptor binding and CCR chemokine receptor binding 
(Figure 59). 
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Figure 60: Gene ontological enrichment analysis – Influence of coffee charcoal extract 
(500 mg/ml) on LPS/IFNγ-stimulated gene expression (data from second gene expression 
analysis procedure, 20/03/2014). 
Enrichment analysis of genes that were up-regulated after simultaneous treatment with LPS/IFNγ and 
charcoal extract (500 mg/ml) compared to single LPS/IFNγ-stimulation (regulation-factor ≥ 10 vs. 
LPS/IFNγ-stimulation; total: 195 genes). Analysis was performed using WEB-based GEne SeT 
AnaLysis Toolkit (WebGestalt software, version 1/30/2013). Presented are categories including two or 
more genes; hypergeometric test with Multiple Test Adjustment BH; categories with the ten lowest 
significance levels (adjusted p-values) are highlighted in grey. 
Genes that were up-regulated more than 10-fold compared to LPS/IFNγ-stimulation can be 
clustered in significantly enriched categories associated with cell motility such as cell migration 
and leukocyte migration and cellular response to corticosteroid stimulus (Figure 60). 
3.3.5 Effect of aqueous myrrh extract on gene expression profile of human M1-
macrophages 
The influence of aqueous myrrh extract (500 µg/ml) on gene expression of human M1-
macrophages was assessed compared to untreated cells (Table 31). 
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Table 31: Influence of aqueous myrrh extract (MYA) on number of regulated genes compared to 
untreated control (u.c.) (data from second gene expression analysis procedure, 17/04/2014). 
Signal MYA / 
Signal u.c. 
Number of 
regulated genes 
> 1000 1 
> 100 20 
> 10 678 
< 0.1 255 
< 0.01 0 
< 0.001 0 
 
Figure 61 presents a visualisation of the gene ontological enrichment analysis.  
 
Figure 61: Gene ontological enrichment analysis of gene up-regulation after single treatment 
with aqueous myrrh extract (500 mg/ml) 
Enrichment analysis of genes that were up-regulated after single treatment with aqueous myrrh extract 
(500 mg/ml) (regulation-factor ≥ 10; total: 678 genes). Analysis was performed using WEB-based 
GEne SeT AnaLysis Toolkit (WebGestalt software, version 1/30/2013). Presented are categories 
including two or more genes; hypergeometric test with Multiple Test Adjustment BH; categories with 
the ten lowest significance levels (adjusted p-values) are highlighted in grey. 
Results   90 
 
 
Genes that were up-regulated more than 10-fold compared to untreated control can be 
clustered in significantly enriched categories associated with chemokine signalling including 
chemokine and cytokine activity (Figure 61). 
 
Figure 62: Gene ontological enrichment analysis of gene down-regulation after single 
treatment with aqueous myrrh extract (500 mg/ml) 
Enrichment analysis of genes that were down-regulated after single treatment with aqueous myrrh 
extract (500 mg/ml) (regulation-factor ≥ 10; total: 255 genes). Analysis was performed using WEB-
based GEne SeT AnaLysis Toolkit (WebGestalt software, version 1/30/2013). Presented are 
categories including two or more genes; hypergeometric test with Multiple Test Adjustment BH; 
categories with the ten lowest significance levels (adjusted p-values) are highlighted in grey. 
Genes that were down-regulated more than 10-fold after treatment with aqueous myrrh extract 
compared to untreated control can be clustered in significantly enriched categories associated 
with cell cycle regulation such as cell cycle checkpoint, nuclear division and mitosis (Figure 
62). 
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4 Discussion 
4.1 Chamomile flower 
4.1.1 Extract characteristics 
Varying quality and origin of the plant material as well as different extraction methods result in 
significant differences in pharmaceutical quality and hence therapeutic effect of chamomile 
preparations. The place of cultivation determines for example the composition of the essential 
oil whereby bisabololoxid-A or –B rich strains as well as varying matricin content can be found. 
The extraction solvent as well as extraction method determines the composition of the finished 
extract. In contrast to pure aqueous extracts, which contain only water soluble flavonoids and 
mucilages, ethanolic-aqueous extracts contain polar (flavonoids) as well as apolar (essential 
oil) components (Schilcher 2004). The essential oil content is determined by the ethanol-water 
ratio, whereby higher ethanol concentrations e.g. 70 % (v/v) lead to an essential oil 
concentration of 0.25 %, in contrast to an ethanol concentration of 40 % (v/v), which leads to 
0.10 % essential oil concentration (Münzel and Huber 1961). 
In the fixed combination Myrrhinil-Intest®, a dried chamomile flower extract is processed. The 
dried extract was obtained after ethanolic (60 % m/m) extraction of chamomile flowers with a 
drug-extract-ratio of 4-6 to 1. 
4.1.2 Spasmolytic activity of the chamomile flower extract 
The antispasmodic effects of chamomile flower have been demonstrated in several animal 
models (Hava and Janku 1957; Achterrath-Tuckermann et al. 1980; Forster et al. 1980). 
Purpose of the present study was to characterise the spasmolytic activity of the chamomile 
flower extract used in Myrrhinil-Intest® and to define an effective concentration range using a 
well-established in vitro model (Michael 2008). Therefore, the extract was tested in different 
concentrations, using isometric tension measurement in isolated rat small intestinal 
preparations. 
The examined chamomile flower extract inhibited the ACh-induced contractions concentration-
dependently. The highest concentration tested decreased the contractions down to 56 %. In 
this experiment setting, a half maximal inhibitory concentration of 160.7 µg/ml was determined. 
These findings are in accordance with previous studies, where the spasmolytic activity of 
chamomile flower extract and components thereof was examined. Forster and co-workers 
reported that an ethanolic chamomile flower extract (31 % v/v; DER: 1:3.5) shifted the 
concentration-response curve of the spasmogenic substances acetylcholine and histamine to 
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the right in a dose-dependent manner (Forster et al. 1980). Investigating its inhibitory effect on 
ACh-induced contractions of guinea-pig ileum, Achterrath-Tuckermann et al. (1980) found that 
total chamomile flower extract (38.5 % v/v; DER: 1:4-4.5) effectively inhibited the spasmogenic 
actions of barium chloride, histamine, acetylcholine, serotonin and bradykinin. Responsible for 
the spasmolytic activity are flavonoids (apigenin > quercetin > luteolin > kaempferol) and their 
glycosides, but also the lipophilic compounds of the essential oil like bisabolol and 
bisabololoxide A and B (Achterrath-Tuckermann et al. 1980). 
It was found by Hörhammer and confirmed later, that the spasmolytic effect of the chamomile 
flower components is mediated directly at the muscle cells (musculotrop) (Hörhammer et al. 
1963; Achterrath-Tuckermann et al. 1980). A possible mechanism of action was provided by 
Maschi and co-workers, who reported, that inhibition of cAMP-phosphodiesterase (cAMP-
PDE) is a potential mechanism responsible for the spasmolytic effects. Inactivation of cAMP-
PDE leads to elevated intracellular cAMP levels which cause relaxation in gastrointestinal 
muscle. Especially after apigenin and luteolin application, the activity of human cAMP-PDE 
was decreased (Maschi et al. 2008).  
A clinical study (prospective, randomised, double-blind) by de la Motte’s group confirmed the 
effectiveness of a co-medication with chamomile flower for the treatment of acute diarrhea in 
children (six month to five years old) (de la Motte et al. 1997). These findings are supported by 
an in vivo study by Di Carlo, who reported a reduced intestinal transit time in mice after 
intraperitoneal administration of the chamomile flavonoid apigenin (12.5 – 50 mg/kg) amongst 
others (Di Carlo et al. 1993). 
Another aspect of the present studies was the revision of spasmolytic effects under 
inflammatory conditions. As previously pointed out, inflammation has been found to play a 
crucial role in the pathophysiology of functional bowel disorders such as IBS. Persisting 
inflammatory processes can lead to a number of functional and structural alterations in the 
concerned tissue impairing contractility and mucosal barrier function. It is well established that 
inflammation markedly alters motility patterns of the gastrointestinal tract. Phasic and tonic 
contractions have been shown to be suppressed, whereas the giant migration peristaltic 
contractions of large amplitude appear to be increased in frequency generating diarrheal 
symptoms associated with inflammation (Malykhina and Akbarali 2004). 
Several studies reported a decreased small intestinal motility after induced inflammation 
(Moreels et al. 2001; Demedts et al. 2006; Grossi et al. 1993). Since these alterations in motility 
could impact the spasmolytic activity of chamomile flower extract, isometric tension 
measurement was repeated after inflammation was induced using an in vitro TNBS 
inflammation model (Warstat 2004). The spasmolytic activity of the examined chamomile 
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flower extract was comparable in inflamed tissue and similar concentrations induced a half 
maximal inhibitory effect (IC50 in untreated preparations: 160 µg/ml vs. IC50 in inflamed 
preparations 126.1 µg/ml). 
4.1.3 Anti-inflammatory activity of chamomile flower 
The anti-inflammatory activity of chamomile flowers is well established and reported in 
literature (Della Loggia et al. 1990; Tubaro et al. 1984; Al-Hindawi et al. 1989; Gerritsen et al. 
1995). 
The present study aimed to characterise the anti-inflammatory potential of the chamomile 
flower extract used in Myrrhinil-Intest®. Based on the indication area, the studies focused on 
the intestinal tract. 
In a first set of experiments, the effect of the chamomile flower extract was examined in a 
TNBS inflammation model. TNBS is a well-established model substance to induce 
inflammation in the gastrointestinal tract (Blumberg et al. 1999). The advantages and 
limitations of this in vitro model have been discussed earlier. Briefly, it provides the advantage 
of a fast and cost efficient screening method for anti-inflammatory agents, since it effectively 
models acute inflammatory processes. However, its limitations as an in vitro model lacking an 
intact cardiovascular system are obvious, since various hormonal and neuronal influences are 
absent. Nonetheless, the TNBS-induced morphological, immunohistochemical, 
molecularbiological and functional changes as results of acute inflammatory processes in the 
in vitro model correlate with findings in vivo and establish the capability of the in vitro model as 
an alternative to in vivo studies (Warstat 2004; Michael et al. 2012). It is not surprising that 
inflammatory processes can be observed in an in vitro model although systemic circulation is 
lacking. The immune system of the gastrointestinal tract, also described as gut associated 
lymphoid tissue, hosts a high number of cells of the innate and adaptive immune system which 
mediate inflammation (Miura et al. 2011). 
In the present studies, the degree of TNBS-induced inflammatory processes was estimated by 
three different parameters: morphological damage, contractility and TNFα gene expression. 
TNBS reduced mucosa layer thickness of ileal preparations by about 20 %. This reduction is 
attributed to necrotic processes as demonstrated earlier by Michael, who performed 
immunohistochemical studies with Sytox Green (Michael 2008).  
The ACh-induced contractions of small intestinal preparations are reduced by about 30 %. The 
mechanisms behind this decrease in contractility is controversially discussed. Alterations in 
nonadrenergic-noncholinergic signalling as well as alterations in calcium-mobilisation amongst 
others seem to contribute to the loss in functionality (Poli et al. 2001; Shi and Sarna 2000). 
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Furthermore, TNBS treatment leads to an increased production of TNFα-mRNA by the factor 4, 
which confirms the involvement of inflammatory processes. In vivo studies confirm an 
increased TNFα gene expression in inflamed tissue after TNBS treatment (Shi et al. 2011; 
Strober and Fuss 2006). 
 
The anti-inflammatory activity of chamomile flower extract could be confirmed histologically 
whereby an intermediate concentration (3 mg/ml) inhibited the TNBS-induced reduction of 
mucosal layer thickness. However, high concentration of chamomile flower extract (30 mg/ml) 
led to a further decrease in mucosal layer thickness, indicating unspecific opposing effects, 
which occur in higher concentrations. 
These observations could be reinforced in functional studies looking at the TNBS-induced 
contractility decrease. Intermediate concentrations of the chamomile flower extract (3 and 
10 mg/ml) inhibited the TNBS-induced reduction of ACh-induced contractions in small 
intestinal preparations. After chamomile treatment, the preparations responded to the 
spasmogenic stimulus ACh to the same extent as the untreated control. The higher 
concentrations however could not inhibit this decrease in contractility, yet it further reduced the 
contractile response. An inverted U-shape concentration-response relation is quite commonly 
seen in the pharmacology of herbal preparations, whereby higher concentrations often induce 
unspecific effects which can negatively affect physiological processes. 
Analysis of the TNFα gene expression revealed that chamomile flower extract suppressed the 
TNBS-induced overexpression of TNFα in all concentrations tested (0.1–100 mg/ml). This 
leads to the impression that the gene expression of TNFα is affected by chamomile flower 
extract in much lower concentrations and involves the suspicion that unspecific effects occur 
in the concentrations tested. However, this observation supports the assumption that the 
reported effects on TNBS-induced morphological damage and contractility decrease are 
induced by anti-inflammatory effects, since TNFα is a major pro-inflammatory mediator and its 
gene expression is induced in the early stages of inflammation.  
To validate the previous results and to get a more precise concentrations response profile a 
simplified inflammation model was used. In this cell culture model, LPS was used to induce a 
pro-inflammatory response from human differentiated macrophage like cells. This model 
allows a more precise investigation of the release of pro-inflammatory TNFα, since one 
monoclonal cell type can be observed. Thus, a potential interference by heterogeneity of 
experimental animals and molecular mechanisms of other cell types for example can be 
excluded. 
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Chamomile flower extract inhibited the LPS-induced TNFα release from THP-1 cells 
concentration dependently down to 28 % with an IC50 of 438.8 µg/ml.  
Since the occurrence of unspecific effects in higher concentrations is known from previous 
experiments, cytotoxicity testing was performed to exclude potential interferences with the 
observed inhibition of TNFα release. LDH release as a measure for necrotic cell death was not 
influenced by chamomile flower extract. In the highest concentration tested (1000 µg/ml) 
chamomile flower extract reduced metabolic activity down to 70 %. The resulting IC50 of 
3108 µg/ml in relation to the IC50 for TNFα release resulted in a selectivity index of 7.08, which 
means that a reduction of metabolic activity occurs in 7-fold higher concentrations than the 
inhibition of TNFα release.  
The observed suppression of TNBS-induced gene expression of TNFα and the inhibition of 
LPS-induced TNFα release could be one possible mechanism mediating the anti-inflammatory 
effects of chamomile flower extract. Yet, further details about mechanisms of action are known 
from literature. Chamazulene, α-bisabolol and flavonoids like apigenin possess the highest 
anti-inflammatory activity against pro-inflammatory agents by inhibiting 5-lipoxygenase and 
therefore the formation of pro-inflammatory leukotriene B4 (Ammon et al. 1996). Furthermore, 
it was found that an aqueous chamomile flower extract exerts its anti-inflammatory activity via 
inhibition of cyclooxygenase-2 (COX-2) enzymes (Srivastava et al. 2009). Both 5-lipoxygenase 
and COX-2 are key enzymes in the conversion of arachidonic acid into pro-inflammatory 
leukotrienes or prostaglandins respectively, which contribute to the regulation of the cytokine 
expression profile. 
Microarray gene expression analysis 
Gene expression analysis was performed to assess the influence of chamomile flower extract 
on the gene expression profile of stimulated human macrophages. Therefore, a model to study 
activated M1-macrophages was used, which has been characterised earlier (Jaguin et al. 
2013).  
LPS/IFNγ-stimulation triggers an inflammatory response, which can be characterised by an 
up-regulation of genes associated with innate and adaptive immune system. This was 
observed in both gene expression analysis experiments. A significant number of genes 
associated with chemokine signalling with functions including chemoattractant activity, 
chemokine activity and CCR chemokine receptor binding was up-regulated more than 10-fold 
after LPS/IFNγ-stimulation according to a gene ontological enrichment analysis (WebGestalt 
software, version 1/30/2013). Chemokines are important mediators in the early phase of 
immune response as their main function is to induce chemotaxis of reactive immune cells. 
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Moreover, a significant number of genes associated with the kynurenine pathway of tryptophan 
metabolism with functions including indoleamine 2,3-dioxygenase activity and tryptophan 2,3-
dioxygenase activity were up-regulated more than 10-fold. Upon immune stimulation and 
cytokine release, enzymes like indoleamine 2,3-dioxygenase (IDO) are strongly up-regulated 
to convert systemic tryptophan to N-formylkynurenine. Conversion of tryptophan to kynurenine 
- as part of the immune defence - is a nearly universal response to IFNγ-release (Moffett and 
Namboodiri 2003). However, it was found, that a simultaneous stimulation with LPS effectively 
potentiates IFNγ-induced IDO activity (Hissong and Carlin 1997). The prevailing view is that 
tryptophan catabolism acts to reduce the amount of tryptophan available to pathogens 
(‘tryptophan depletion theory’; Moffett and Namboodiri 2003).  
On the other hand, a significant number of cells associated with cell cycle regulation were 
down-regulated more than 10-fold. That appears plausible since monocytes/macrophages 
undergo various changes in survival and death signalling. Under normal circumstances, 
monocytes circulate in the bloodstream for a very short time before undergoing spontaneous 
apoptosis, which is induced by a constitutively active cell death program. Upon differentiation 
to macrophages and subsequent activation, apoptosis is blocked, sustaining a prolonged 
survival of monocytes. Macrophages, have acquired mechanisms that inhibit the apoptotic 
program and activate survival pathways responsible for promoting a longer life span (Parihar 
et al. 2010).  
Furthermore it is known, that numerous transcriptional repressors are amongst the repressed 
genes, which are responsible for regulation and resolution of the inflammatory response 
(Medzhitov and Horng 2009). Overall, the number and magnitude of expression of induced 
genes is almost well balanced by the numbers of repressed genes. 
 
To test the influence of chamomile flower extract on the gene expression profile of the 
macrophages, a concentration of 200 µg/ml was chosen based on previous experiments. This 
concentration lies in the lower region of the effective concentration range but was considered 
favourable in light of preliminary flow cytometry experiments with the same cell type. 
Treatment with chamomile flower extract (200 mg/ml) did not markedly influence the up- or 
down-regulation of genes compared to a single LPS/IFNγ-treatment. Only a number of 78 
genes were up-regulated more than 10-fold, whereas no genes were up-regulated more than 
100-fold compared to LPS/IFNγ. A number of 104 genes were down-regulated more than 10-
fold, whereas no genes were down-regulated more than 100-fold. 
Of the 104 genes that were down-regulated compared to LPS/IFNγ, two genes could be 
clustered in a significantly enriched GO-category (CXCR receptor binding). The two genes that 
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were clustered in this category are the chemokine receptor ligand 12 and 13 (CXCL12 and 
CXCL13). As indicated earlier, chemokines are important mediators in the early phase of 
immune response as their main function is to induce chemotaxis of reactive immune cells. The 
expression of chemokines and their corresponding receptors is triggered by pro-inflammatory 
stimuli like LPS and IFNγ, as it was observed in this studies. The down-regulation of these 
genes could hint to a mechanism of the anti-inflammatory activity of chamomile flower. 
However, it is apparent, that more mechanisms are involved within the complex anti-
inflammatory interplay. One reason for the weak manifestation of influenced gene expression 
could be a too low test concentration. 
Taken together with the results from the TNBS- and LPS-inflammation model, the existence of 
anti-inflammatory effects could be demonstrated for the chamomile flower extract used in 
Myrrhinil-Intest®. 
4.2 Myrrh 
4.2.1 Extract characteristics 
Myrrhinil-Intest® contains myrrh, whereby the powdered substance of the dried resin and no 
extracts thereof is processed in the finished product. Therefore it was necessary to create 
different extracts which contain the spectrum of polar and non-polar ingredients to be 
investigated. For this purpose, an aqueous and an ethanolic extract was created. The water 
soluble gum fraction of powdered myrrh is composed of a heterodisperse mixture of 
proteoglycans with a dominating amount of uranic acid rich compounds (Wiendl et al. 1995) 
An extract of the ethanol-soluble fraction was provided by DS Pharma. It consists of the 
ethanol-soluble resin, which is comprised of sesquiterpenes and diterpenic (commiphoric 
acids) and triterpenic acids as well as their esters (Hanus et al. 2005). Due to the water steam 
distillation process the volatile oil was removed and is therefore not present in the finished 
ethanolic extract. 
4.2.2 Spasmolytic activity of myrrh 
The traditional use of myrrh for the treatment of diarrhea has been reported and thereafter 
been investigated in vivo determining antidiarrheal activity in an intestinal loop mice model 
whereby Commiphora species inhibited the toxin induced hypersecretion (Claeson and 
Samuelsson 1989). Smooth muscle relaxing properties of ethyl acetate myrrh extract fractions 
have been studied in vitro using an isolated guinea pig ileum model. The sesquiterpen 
T-cadinol seems to be the major active substance inducing muscle relaxing effects (Claeson 
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et al. 1991a). Based on these findings, the spasmolytic activity of the ethanolic myrrh extract 
only was investigated. 
The results of the present study confirm the postulated muscle relaxing effects. The ACh-
induced contractions of rat small intestinal preparations were reduced concentration-
dependently down to about 10 % with a half maximal inhibitory concentration of 157.7 µg/ml. 
Moreover, the basal muscular tone was reduced after application of ethanolic myrrh extract 
(150 µg/ml). 
Further studies using isolated rat aorta and a radioligand binding assay indicated that the 
muscle relaxing effects could be mediated by calcium antagonistic properties of the 
sesquiterpene T-cadinol and other terpenic compounds (Claeson et al. 1991b; Zygmunt et al. 
1993; Andersson et al. 1997). Therefore, the calcium antagonistic properties of the ethanolic 
myrrh extract were examined in this study. It was found, that the myrrh-induced decrease of 
basal muscular tone could be antagonised with the calcium channel agonist Bay K8644. These 
effects could be reproduced with the well-known calcium channel antagonist nimodipine. An 
evaluation of the concentration-response relation revealed a significant right-ward shift of the 
agonistic concentration-response curve, indicating a competitive antagonism. However, these 
observations were made at comparably low myrrh concentrations (150 µg/ml). To get a 
complete picture of the pharmacological activity it was of interest to test higher concentrations 
additionally.  
Therefore, repeated concentration-response curves with increasing concentrations of 
ethanolic myrrh extract have been recorded and detailed analysis of the concentration-effect 
relation revealed that depending on the concentration both competitive and non-competitive 
elements contribute to the overall effect. For a better characterisation those elements were 
quantified and analysed separately. This elucidates that the competitive effects are mainly 
exerted in lower concentrations whereas non-competitive antagonistic behaviour is found in 
higher concentrations. Dual antagonism consisting of competitive and non-competitive 
elements is quite commonly found in biological drug testing. Especially in plant extracts these 
dual properties seem reasonable as a complex mixture of structurally related components 
contribute to the overall effect to a different extent and in varying modes of action. As previously 
mentioned Andersson and co-workers found that besides T-cadinol other sesquiterpenes 
exerted calcium antagonistic effects with varying potencies (Andersson et al. 1997). Moreover 
it is likely that especially in higher concentrations besides calcium channels other targets are 
influenced by terpenic or other compounds present in the ethanolic fraction besides the 
sesquiterpenes. It can be concluded from the data of the present study that ethanolic myrrh 
extract behaves mainly as a competitive antagonist on which, if higher concentrations are used 
a non-competitive inhibiting action is superimposed. 
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As previously pointed out, induced inflammation leads to a decreased motility of small intestinal 
tissue (Moreels et al. 2001; Demedts et al. 2006; Grossi et al. 1993). Moreover, it has been 
reported that calcium currents were suppressed upon inflammation (Akbarali et al. 2000; 
Kinoshita et al. 2003). Liu’s group further showed that the current suppression was associated 
with a down regulated expression level of L-type calcium channels in membranes of circular 
smooth muscle cells of inflamed intestinal tissue (Liu et al. 2001). These observations could 
have an impact on the spasmolytic activity mediated by calcium channel blockade. The 
antispasmodic effects were therefore revised under inflamed conditions additionally. 
Despite the reported inflammation-induced alterations of gastrointestinal contractility, the 
observed effects have overall been found to be comparable between healthy and inflamed 
conditions. Inhibition of ACh-induced contraction was demonstrated for both untreated and 
inflamed preparations. However, comparing the effect on induced contractions in inflamed and 
untreated tissue it must be stressed that the IC50 in inflamed tissue was slightly higher than in 
untreated tissue (277.4 µg/ml vs. 157.7 µg/ml). This can be explained by functional impairment 
of cholinergic neurotransmission as has been reported after induction of TNBS-mediated 
inflammation in vivo (Shi and Sarna 2000; Poli et al. 2001). The reported down-regulation of 
L-type calcium channels in inflamed intestinal tissue (Khan 1999) and subsequent impairment 
of calcium influx could yet be another possible explanation.  
4.2.3 Anti-inflammatory activity of myrrh 
The anti-inflammatory activity of myrrh was investigated in different inflammation models, 
whereby both the aqueous and the ethanolic extract were tested. In a first set of experiments 
the in vitro TNBS-inflammation model was used.  
Aqueous myrrh extract (1 mg/ml) inhibited the TNBS-induced reduction of mucosal layer 
thickness. This observation is in accordance with results from the isometric tension 
measurement, where the aqueous myrrh extract (0.1 mg/ml) inhibited the decrease in 
contractility induced by TNBS. Yet, lower concentrations were able to antagonise the TNBS 
effect, whereby higher concentrations were not effective in this model. In line with these 
observations, the TNBS-induced overexpression of TNFα-mRNA, which is produced as 
response to a pro-inflammatory stimulus, was significantly reduced by intermediate 
concentrations of aqueous myrrh extract (1 and 10 mg/ml). This supports the assumption that 
the observed amelioration of TNBS-induced damages in morphology and contractility is due 
to anti-inflammatory effects. 
Ethanolic myrrh extract (0.15 mg/ml) could not ameliorate the morphological damage induced 
by TNBS. Additionally, it could not antagonise the TNBS-induced decrease in contractility, yet 
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it induced a further decrease in ACh-induced contraction. Taking the demonstrated, very 
effective spasmolytic activity into consideration, it appears plausible, that the applied calcium 
channel blockade by components of the ethanolic myrrh extract for 30 minutes leads to a 
permanent decrease in ACh-induced contractions. This applies especially in high 
concentrations (1 mg/ml) since non-competitive antagonistic effects are dominating in this 
concentration range. A clear assumption regarding anti-inflammatory effects can therefore not 
be drawn using this model. Moreover, looking at the molecularbiological level, no statistically 
significant reduction of the TNBS-induced overexpression of TNFα-mRNA could be observed, 
yet the levels of TNFα gene expression after treatment with ethanolic myrrh extract were below 
those induced by TNBS. 
To obtain a clear outcome about anti-inflammatory effects, is was necessary to use a simplified 
model without interferences by other pharmacological effects like spasmolytic activity. 
Therefore, macrophage cell lines and an LPS-inflammation model was used to investigate the 
production of pro-inflammatory mediators such as TNFα and nitric oxide (NO). Ethanolic myrrh 
extract inhibited the LPS-induced TNFα release from differentiated THP-1 cells concentration-
dependently down to 2 % with an IC50 of 60.65 µg/ml. Cytotoxicity testing showed, that LDH 
release as a measure for necrotic cell death was not influenced in the concentrations tested. 
In the highest concentration tested (200 µg/ml) metabolic activity was reduced down to 48 %. 
The IC50 of metabolic activity in relation to the IC50 of TNFα release resulted in a selectivity 
index of 5.8, which means that a reduction of metabolic activity occurs in 6-fold higher 
concentrations than the inhibition of TNFα release. In accordance with this findings, ethanolic 
myrrh extract inhibited the LPS-induced NO release from murine macrophages (RAW 264.7 
cells) down to 10 % with an IC50 of 24.24 µg/ml. It should be mentioned, that the murine 
system responds to inflammatory stimuli with a high production of NO in line with an 
overexpression of inducible NO synthase (iNOS) (Nathan 1992), whereas iNOS expression in 
human monocytes and macrophages has been difficult to demonstrate (Nussler et al. 1995; 
Denis 1991). These differences between species could explain the lower IC50 value for the 
NO-inhibition, since the murine system might respond more effectively to inhibitory effects of 
the ethanolic myrrh extract.  
Aqueous myrrh extract exerted only in the highest concentration tested (1000 µg/ml) a 
moderate inhibitory effect on LPS-induced TNFα release from THP-1 cells and NO release 
from murine macrophages. Since only the highest concentration induced an effect, no 
conclusive concentration-response relation could be established.  
Looking at the effects induced on basal TNFα or NO release, aqueous myrrh extract 
interestingly induced a release of TNFα or NO respectively in the highest concentration. These 
effects however occurred only in very high concentrations and are relatively weak compared 
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to those induced by LPS. Furthermore, neither LDH release nor metabolic activity of the cells 
was affected in this concentrations. Since related effects were observed in gene expression 
analysis, this issue will be discussed in that section.  
Taken together, the molecularbiological effects, which could be investigated with the applied 
methods, suggest, that the anti-inflammatory effects of ethanolic myrrh extract are more 
pronounced than those induced by the aqueous extract. Since the functional and histological 
methods using isolated small intestinal preparations were not suitable to evaluate anti-
inflammatory effects of the ethanolic extract due to spasmolytic activity, the anti-inflammatory 
effects could not be demonstrated in these methods. 
However, for the aqueous myrrh extract, these functional and histological methods 
demonstrated an ameliorating effect of the TNBS-induced damage, which could be attributed 
to anti-inflammatory effects seen by analysis of TNFα gene expression in the intestinal tissue. 
It was demonstrated, that the overall anti-inflammatory effect of myrrh is mediated through 
suppression of TNFα and NO release. The findings are in accordance with results from other 
studies where an aqueous myrrh extract reduced LPS-induced TNFα, NO and prostaglandin 
E2 (PGE2) release in peritoneal macrophages (Kim et al. 2012). In this study the aqueous 
extract was obtained by extracting powdered myrrh in boiling water for two hours, without 
previous removal of the ethanol-soluble resin fraction. This could explain the fact, that this 
aqueous extract reduced pro-inflammatory cytokine production, whereas the aqueous extract 
of the present study did not. Remaining components of the ethanol-soluble resin which were 
dissolved in water under the extracting conditions of Kim et al. could have induced the anti-
inflammatory effect. These compound would appear in the ethanolic extract used in this study, 
which is in accordance with the obtained results. Several animal studies confirmed the anti-
inflammatory property of myrrh, whereby it reduced the growth of carrageenan or 
formaldehyde induced oedemas and decreased prostaglandin E2 or NO release in inflamed 
tissue (Su et al. 2011; Su et al. 2012; Tariq et al. 1986; Atta and Alkofahi 1998). 
Microarray gene expression analysis 
To determine its influence on the gene expression profile of stimulated native human 
macrophages, ethanolic myrrh extract was applied to the cells simultaneously with LPS/IFNγ 
for 24 hours. For this experiments a concentration of 30 µg/ml was selected based on previous 
studies and preliminary flow cytometry experiments.  
Ethanolic myrrh extract led to more than 10-fold up-regulation of 84 genes and more than 10-
fold down-regulation of 202 genes compared to a single LPS/IFNγ-treatment. Genes that were 
affected could be clustered in significantly enriched GO-categories belonging to the molecular 
function of oxidoreductase activity. However, oxidoreductases are enzymes, which catalyse 
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redox reactions and their functioning belongs to basic cell biological processes which cannot 
clearly be attributed to anti-inflammatory pathways. 
Aqueous myrrh extract (500 µg/ml) had no major influence on the gene expression profile of 
LPS/IFNγ stimulated native human macrophages. Only a number of 25 genes was up-
regulated more than 10-fold and a number of 112 genes was down-regulated more than 10-
fold compared to a single stimulation with LPS/IFNγ. Neither of those genes could be clustered 
in a significantly enriched GO-category.  
However, in line with findings made in the LPS-inflammation model in human and murine 
macrophages, single treatment with aqueous myrrh extract influenced the basal gene 
expression of the native human macrophages. Compared to untreated control, single 
treatment with aqueous myrrh extract led to a more than 10-fold up-regulation of 678 genes of 
which 20 are up-regulated more than 100-fold and one gene is up-regulated more than 1000-
fold. Gene ontological enrichment analysis revealed, that a significant number of those genes, 
that were up-regulated more than 10-fold, can be associated with immune response such as 
chemokine activity and cytokine receptor activity. On the other hand, genes that were down-
regulated more than 10-fold can be associated with mitosis and cell cycle regulation. This 
suggests, that components of aqueous myrrh extract itself trigger an inflammatory response 
since similar effects could be observed after single LPS/IFNγ-stimulation. This observation is 
in accordance with earlier findings of an induced TNFα-production in THP-1 cells and an 
induced NO release in murine macrophages upon incubation with aqueous myrrh extract. 
However, it was seen in the methods testing TNFα and NO release, that the stimulating effect 
was far lower compared to that induced by LPS in a concentration of 100 ng/ml. 
An initial consideration suggests the possibility of a contamination of the extract with 
lipopolysaccharides. However, a LAL endotoxin assay reported no endotoxin contamination of 
the extract in the concentrations tested. 
Another possibility is, that water-soluble myrrh components in the extract induce these effects. 
The water soluble gum fraction of powdered myrrh is composed of a heterodisperse mixture 
of proteoglycans with a dominating amount of uranic acid rich compounds (Wiendl et al. 1995). 
It is possible that among those polysaccharides structures can be found, which trigger immune 
response for example by activating certain pattern recognition mechanisms. Similarly, 
proteogylcans from mushrooms like Phellinus linteus (Hymenochaetaceae) are known to 
induce macrophage activation via toll-like receptor 2 and/or toll-like receptor 4 mediated 
pathways (Kim et al. 2004). 
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4.3 Coffee charcoal 
4.3.1 Extract characteristics 
Coffee charcoal is described as the milled, roasted to blackening outer seed parts of green 
dried Coffea Arabica L. fruits. Kuhn and Schäfer (1939) have analysed the ingredients of coffee 
charcoal in comparison to green coffee. Depending on the roasting degree, the powdered 
substance contains 0.8 to 1.0 % caffeine which correlates to 75 % of the content in roasted 
coffee. The chlorogenic acid concentration is about 1.89 %, the caffeic acid concentration 
about 0.31 % and the trigonelline concentration with 0.29 % approximately half of the content 
in roasted coffee (Kuhn and Schäfer 1939). Examination of the absorption capacity showed an 
increase with rising roasting times. Coffee charcoal (1.0 g) binds about 50 mg methylene blue, 
whereas green coffee was able to bind only 9.0 mg. However, the absorption capacity of 
activated charcoal was not achieved (Kuhn and Schäfer 1939). 
For the pharmacological experiments in this study a filtrated aqueous extract was used, which 
therefore contained water-soluble substances like caffeine, chlorogenic acid and trigonelline. 
Diterpenes like kahweol and cafestol were partially removed by the filtration process. 
4.3.2 Spasmolytic activity of coffee charcoal 
Coffee charcoal is traditionally used as an antidiarrheal whereby typically an average daily 
dose of 9.0 g is recommended by the Commission E. For this indication the monograph refers 
to its absorbent and astringent properties, which mediate the therapeutic effect similar to 
activated charcoal. 
The spasmolytic activity of an aqueous coffee charcoal extract, which could contribute to an 
antidiarrheal effect, was examined in the present study and no influence on ACh-induced 
contraction was found. Additionally no effect on basal muscular tone was found in preliminary 
experiments (results are not presented). 
The effect of coffee on gastrointestinal motor function is discussed controversially. In vivo 
studies indicated an increase in colonic motor activity (Brown et al. 1990; Rao et al. 1998), 
whereas no clear effect on gastric motor function was found (Chan et al. 2000; Boekema et al. 
2000). However, because of a latency time of several minutes it appears that those in vivo 
effects are mediated by neural mechanisms or gastrointestinal hormones and no direct action 
on the colon occurs. Some older in vitro studies, performed with instant and decaffeinated 
coffee, report cholinomimetic or muscarinic actions of some coffee compounds and a relaxing 
activity for caffeine particularly (Tse 1992; Atkinson 1976), however clear evidence for these 
reported effects is lacking to date.  
Discussion   104 
 
 
It is likely, that the process of overroasting in the manufacturing process of coffee charcoal has 
destroyed potential agents and the final mass ratio of those compounds in the powdered 
substance is too low to mediate any pharmacological effects. 
Moreover, the information provided by the in vitro study performed in the present study using 
isolated organs is limited, since indirect effects, mediated by neuronal or gastrointestinal 
messengers are neglected.  
4.3.3 Anti-inflammatory activity of coffee charcoal 
The investigation of anti-inflammatory activity of an aqueous extract from coffee charcoal, 
which is processed in Myrrhinil-Intest® was conducted using the TNBS- and the LPS-
inflammation model in isolated small intestinal preparations and human macrophage like cells 
respectively. 
In the TNBS-inflammation model no anti-inflammatory effect was observed. Coffee charcoal 
did not influence the TNBS-induced morphological damage or the contractility decrease of the 
small intestinal preparations. Furthermore, no influence was detected on the TNBS-induced 
overexpression of TNFα-mRNA. 
Investigations on the LPS-induced TNFα release from differentiated THP-1 cells revealed an 
inhibiting effect by coffee charcoal in higher concentrations. TNFα release was suppressed 
down to 56 % compared to single LPS-stimulation. However, the IC50 value was comparably 
high (IC50 = 1886 µg/ml) and the maximal inhibitory effect was much less pronounced than 
the effect induced by the glucocorticoid budesonide, which was used as positive control. 
A potential active compound could be caffeic acid and its quinic acid-ester chlorogenic acid, 
whose anti-inflammatory activities have been described earlier (Koshihara et al. 1984). 
Mechanisms found to be involved include the inhibition of phosphorylase kinase and protein 
kinase A and C (Nardini et al. 2000) as well as suppression of NF-κB and MAPKs (Feng et al. 
2005). Furthermore it has been reported, that caffeic acid directly suppresses interleukin-1 
receptor-associated kinase 1 and 4 (IRAK1 and IRAK4) which are involved in downstream toll-
like receptor 4 signalling (Yang et al. 2013). 
Microarray gene expression analysis 
Gene expression analysis was performed to assess the influence of coffee charcoal extract on 
the gene expression profile of stimulated human macrophages. Therefore, a concentration of 
500 µg/ml was chosen based on previous cell culture studies and preliminary flow cytometry 
experiments.  
Coffee charcoal extract (500 µg/ml) exerted the strongest effects on LPS/IFNγ-induced gene 
up-regulation. It suppressed the LPS/IFNγ-induced expression of the genes CXCL13, 
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CXCL10 and CXCL11 more than 100-fold. A number of 8 genes was suppressed more than 
10-fold. It appears noteworthy, that most of those genes are associated with immune response, 
in particular with chemokine signalling. On the other hand, coffee charcoal extract led to an 
up-regulation of 195 genes by more than 10-fold compared to LPS/IFNγ-stimulation. Those 
genes can be clustered in significantly enriched categories associated with cell motility such 
as cell migration and leukocyte migration and cellular response to corticosteroid stimulus. This 
suggests, that coffee charcoal interferes with the chemotactic response of activated 
macrophages and thereby influences inflammatory response. 
This observation is in accordance with an in vivo study investigating the effect of coffee 
consumption on the immune system which reported, that the chemotaxis activity of 
mononuclear cells was increased in test persons after coffee consumption (Melamed et al. 
1990).  
Adenosine is known to promote neutrophil chemotaxis by activating adenosine receptors 
(Rose 1988). Caffeine as a non-selective adenosine receptor antagonist (Fredholm et al. 1999) 
could therefore be an active substance responsible for influencing the chemotactic response 
of coffee charcoal. Rose was able to show in his study, that the antagonist NECA (5′-(N-
ethylcarboxamido)adenosine) completely reversed the agonist-induced enhancement of 
chemotaxis but did not affect chemotaxis by itself (Rose 1988). Likewise, caffeine could be 
responsible for the inhibition of the LPS/IFNγ-induced chemotactic response in macrophages. 
However, these considerations have to be reinforced in respective studies. 
4.4 Conclusion 
Several clinical studies showed that the fixed combination Myrrhinil-Intest® - containing myrrh, 
chamomile flower and coffee charcoal - is a potent agent against gastrointestinal disorders 
(Langhorst et al. 2013; Lühr 1996; Thilo-Körner 2006). The therapeutic areas for which 
Myrrhinil-Intest® is applied in medicinal practice, covers various gastrointestinal disorders such 
as chronic diarrhea, inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).  
For the investigation of pharmacological effects, spasmolytic and anti-inflammatory activities 
were of interest since mainly these pharmacological effects seem to contribute to the reported 
therapeutic effectiveness. 
The spasmolytic activity is mainly driven by ethanolic myrrh extract, whose calcium 
antagonistic effects led to a relaxation of the smooth muscle in small intestinal preparations. It 
can be assumed, that in vivo myrrh acts locally at the muscle cells of the intestine and no 
absorption of the active ingredients into the circulatory system occurs. Adverse events that 
would follow a systemic action can be derived from the action of therapeutically applied calcium 
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channel blockers for the treatment of cardiac diseases and include bradycardia, low blood 
pressure and reflex tachycardia amongst others. However, in a study conducted by Langhorst 
and co-workers in which 47 patients were treated with Myrrhinil-Intest® (four tablets three times 
daily) for a 12-months period, no cardiovascular adverse events were observed (Langhorst 
et al. 2013). This indicates, that the systemic absorption rate of the active ingredients, which 
are responsible for calcium antagonistic effects, is too low to cause cardiovascular effects. 
The spasmolytic activity of chamomile flower certainly contributes towards the overall effect of 
the fixed combination. Looking at the ability to decrease ACh-induced contractions, chamomile 
flower is somewhat less effective than myrrh, since their IC50 values are comparable, yet 
myrrh induced a stronger maximal inhibitory effect. However, a synergistic effect between 
these two agents cannot be ruled out.  
An in vivo study performed by Kanazawa for the treatment of inflammatory bowel syndrome 
indicated, that pain hypersensitivity and an enhanced colonic motility, which is characterised 
by increased phasic motility and enhanced smooth muscle tone, are independent factors 
contributing to symptom severity of IBS patients (Kanazawa et al. 2008). Effective treatment, 
which addresses one or both factors contributes therefore to the improvement of the overall 
symptom complex. In this context, the application of Myrrhinil-Intest® for the treatment of not 
only diarrheal symptoms but also IBS in general becomes plausible because of the 
antispasmodic effects of its components. However, treatment of multifactorial disorders such 
as IBS should not be based on only one strategy but provide a multi-target approach as it is 
the case for many herbal therapies. 
Inflammation is another factor which has been found to play a crucial role in the 
pathophysiology of IBS. Persisting inflammatory processes can lead to a number of functional 
and structural alterations in the concerned tissue impairing contractility and mucosal barrier 
function. It is well established that inflammation markedly alters motility patterns of the 
gastrointestinal tract. Phasic and tonic contractions have been shown to be suppressed, 
whereas the giant migration peristaltic contractions of large amplitude appear to be increased 
in frequency generating diarrheal symptoms associated with inflammation (Malykhina and 
Akbarali 2004).  
In this regard, the anti-inflammatory activity of Myrrhinil-Intest® could be another strategy to 
improve symptom severity of functional bowel disorders. The anti-inflammatory activity of 
chamomile flower is well established and was reinforced with the extract used in 
Myrrhinil-Intest® and the methods applied in this study. The chamomile flower extract has a 
pronounced anti-inflammatory potential which could be observed in the TNBS-inflammation 
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model using isolated small intestinal preparations but also in the LPS-inflammation model 
using human macrophage like cells.  
The anti-inflammatory potential of myrrh is more complex and components of the aqueous as 
well as the ethanolic extract seem to contribute to the effects. Ethanolic myrrh extract exerts a 
very distinct anti-inflammatory effect in cell culture models with an IC50 ranging from 24 to 
61 µg/ml. Aqueous myrrh extract however ameliorated the damaging effects of the pro-
inflammatory TNBS on intestinal tissue. It is likely, that both effects are exerted via different 
mechanisms which could explain the diverse response rates in the different models used.  
Coffee charcoal did not exert distinct anti-inflammatory effects in the TNBS-inflammation 
model. Using the LPS-inflammation model in macrophage like cells, a decreasing activity on 
TNFα release was observed in high concentrations (IC50 = 1886 µg/ml). These effects are 
likely to be unspecific due to the high half maximal inhibitory concentration and in comparison 
to those induced by myrrh and chamomile of minor significance. However, other 
pharmacological activities could contribute to the therapeutic potential of Myrrhinil-Intest®. It 
was observed in gene expression analysis, that especially the LPS-induced elevated 
chemokine signalling was influenced by coffee charcoal extract. The clinical significance of this 
observation is yet to be questioned. Its absorbent and adstringent properties certainly 
contribute mainly to the overall effectiveness of the fixed combination. 
Taken together, it could be demonstrated, that the components of Myrrhinil-Intest® are able to 
target gastrointestinal disorders by exerting spasmolytic and anti-inflammatory effects. These 
pharmacological effects provide plausibility of the reported clinical effectiveness. 
Further investigations could focus on the identification of active substances within the herbal 
preparations, which are responsible for the spasmolytic and anti-inflammatory effects. This 
knowledge would be beneficial for a future standardisation of the herbal ingredients. Therefore, 
bioguided fractionation should be performed to identify active principles. On the same account, 
it is necessary to perform a phytochemical characterisation of all extracts used in 
Myrrhinil-Intest®. Furthermore, combination analysis of the extracts could be undertaken to 
identify synergistic effects between the herbal ingredients especially in the field of spasmolytic 
activity with chamomile and myrrh, but also for the anti-inflammatory effects. Evidence for 
synergistic effects among the herbal ingredients would for instance reinforce the superiority of 
this combination product over a mono-component product. 
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5 Summary 
The fixed herbal combination Myrrhinil-Intest®, which consists of myrrh, chamomile flower and 
coffee charcoal is marketed in Germany since 1959 and applied in medical practice for the 
treatment of gastrointestinal disorders such as functional diarrhea, irritable bowel syndrome 
and inflammatory bowel diseases.  Myrrh is described as the oleo-gum resin from mainly 
Commiphora molmol Engler (Burseraceae), coffee charcoal are the powdered outer seed parts 
of green dried Coffea Arabica L. (Rubiaceae) fruits, which are roasted to blackening and 
chamomile flowers are the flower heads of Matricaria recutita L. (Asteraceae). 
The clinical effectiveness of Myrrhinil-Intest® for the treatment of various gastrointestinal 
disorders was demonstrated in several clinical studies and is described in various experience 
reports.  
Since market release in 1959, the regulatory requirements for herbal medicinal products have 
underwent major changes. Following the establishment of the German Medicines Act in 1976, 
which introduced a definition of medicinal products, manufacturers were obliged to provide 
proof of quality for the medicinal product, whereby safety and efficacy for in principle well-
known constituents of herbal medicinal products could be demonstrated by the Commission 
E. Myrrhinil-Intest® obtained a subsequent approval within this regulatory context in 2001. 
In the course of further harmonisation across the European Union the Directive on Traditional 
Herbal Medicinal Products (Directive 2004/24/EC) introduced a regulatory framework for 
herbal medicinal products which allows a registration as “traditional herbal medicinal product” 
or marketing authorisation for well-established medicinal products. Within this context, the 
regulatory status for Myrrhinil-Intest® had to be adapted to a traditional use registration and 
new documentation in line with the requirements from the directive specified in § 16a has to 
be provided. One aspect within these requirements concerning pharmacological proof, asks 
for "plausibility of pharmacological effects or efficacy of the medicinal product on the basis of 
long-standing use and experience" (Directive 2004/24/EC § 16a). This knowledge has to be 
reinforced with the provision of supportive preclinical data.   
To address the increasing need for robust preclinical data, aim of the present study was to 
update the pharmacological profile of Myrrhinil-Intest® with the provision of pharmacological 
data obtained with the means of modern biochemical and pharmacological methods. In this 
context the spasmolytic and anti-inflammatory activities were of interest since mainly these 
pharmacological effects seem to contribute to the reported therapeutic effectiveness.  
For the experiments, extracts of myrrh and coffee charcoal were prepared to obtain suitable 
testing agents. The dried extract of chamomile flower, which is used in the finished dosage 
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form was ready to use by dilution in ethanol or DMSO. Coffee charcoal was extracted with 
water to obtain an aqueous extract. The water and the ethanol soluble fraction of myrrh was 
separated by preparing an aqueous and an ethanolic extract.  
Spasmolytic activity was assessed using isolated rat small intestinal preparations. Functional 
investigations were carried out measuring isometric contractions.  
Myrrh and chamomile flower exerted a spasmolytic effect, whereas coffee charcoal induced 
no effect. The spasmolytic activity of myrrh is more pronounced and mediated by inhibition of 
L-type calcium channels, whereby competitive inhibition occurs in lower concentration on 
which non-competitive effects in higher concentration are superimposed.  
To examine anti-inflammatory activity an in vitro TNBS-inflammation model was used. 
Inflammation was induced in rat small intestinal preparations and the influence of the extracts 
on contractility, morphology and TNFα-mRNA expression was detected. These parameters 
were measured using isometric tension measurement, histological analysis and TNFα gene 
expression analysis respectively.   
Furthermore, a LPS-inflammation model was utilised. Thus, LPS was used as a pro-
inflammatory stimulus to activate macrophages or macrophage like cells and the effect of the 
extracts on cytokine signalling was assessed.   
Chamomile flower induced a coherent anti-inflammatory effect which was detectable in both 
the TNBS- and the LPS-inflammation model.   
The anti-inflammatory potential of myrrh provides a complex picture. The aqueous fraction of 
myrrh induced anti-inflammatory effects, which could be observed in the TNBS-inflammation 
model. It ameliorated TNBS-induced contractility decrease, morphological damage and 
overexpression of TNFα-mRNA. However, it had no influence on LPS-induced TNFα release 
from macrophage like cells.   
The ethanolic fraction induced a very pronounced effect in the LPS-inflammation model by 
inhibiting LPS-induced TNFα and NO release. Yet, no effect could be observed in the TNBS-
inflammation model.   
The anti-inflammatory activity of coffee charcoal is of minor potency as it inhibited the LPS-
induced TNFα release only in higher concentrations.  
In order to obtain an insight in the mechanisms underlying any anti-inflammatory activity, gene 
expression analysis was performed. Thus, the influence of the extracts on the gene expression 
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profile of native human macrophages was studied. A LPS/IFNγ mixture was used as pro-
inflammatory stimulus.   
Chamomile flower and coffee charcoal markedly influenced the gene expression profile. 
Especially coffee charcoal inhibited the LPS/IFNγ-induced expression of genes associated 
with chemokine signalling. Ethanolic myrrh extract did not explicitly influence the expression 
of genes that can be associated with inflammatory processes. However, single treatment with 
aqueous myrrh extract resulted in a change in gene expression profile similar to this induced 
by LPS/IFNγ, indicating an immunostimulatory action.  
The presented study demonstrates the pharmacological potential of the herbal ingredients of 
the fixed combination with respect to its spasmolytic and anti-inflammatory activities. Taken 
together, it could be demonstrated, that the components of the herbal combination are able to 
target gastrointestinal disorders by exerting spasmolytic and anti-inflammatory effects which 
reinforce the reported clinical effectiveness.  
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Zusammenfassung 
Das traditionelle pflanzliche Arzneimittel Myrrhinil-Intest® - bestehend aus Myrrhe, 
Kamillenblüten und Kaffeekohle - wird seit 1959 in Deutschland vermarktet. Sein 
Anwendungsgebiet umfasst gastrointestinale Beschwerden wie zum Beispiel funktionelle 
Diarrhoe, Reizdarmsyndrom und chronisch entzündliche Darmerkrankungen. 
Myrrhe bezeichnet das an der Luft gehärtete Gummiharz von hauptsächlich Commiphora 
molmol Engler (Burseraceae). Kamillenblüten sind die Blütenköpfe von Matricaria recutita 
Linné (Asteraceae) und Kaffeekohle wird durch Überröstung von grünen getrockneten 
Kaffeefrüchten (Coffea Arabica Linné, Rubiaceae) gewonnen. 
Die klinische Wirksamkeit des Präparates für die Behandlung von verschiedenen 
gastrointestinalen Beschwerden wurde in mehreren klinischen Untersuchungen und 
Erfahrungsberichten belegt. 
Seit der Markteinführung 1959 haben sich die regulatorischen Anforderungen an pflanzliche 
Arzneimittel gewandelt. Nach der Einführung des Arzneimittelbegriffes mit der Etablierung des 
Arzneimittelgesetzes in Deutschland (1976) oblag es den Arzneimittelherstellern, Belege zur 
Qualität ihres Produktes zu erbringen. Hingegen war es möglich, Unbedenklichkeit und 
Wirksamkeit eines pflanzlichen Arzneimittels mit vom Grundsatz her bekannten Stoffen 
anhand einer Aufbreitungsmonografie der Kommission E zu belegen. Myrrhinil-Intest® erlangte 
im Jahr 2001 im Rahmen dieser Gesetzgebung eine sogenannte Nachzulassung. 
Im Zuge eines Harmonisierungsprozesses innerhalb der Europäischen Union führte die 
Richtlinie über pflanzliche Arzneimittel (Richtlinie 2004/24/EG) eine Gesetzgebung für 
traditionelle pflanzliche Arzneimittel ein, welche neben der Zulassung als Arzneimittel mit vom 
Grundsatz her bekannten Stoffen auch eine Registrierung als sogenanntes „traditionelles 
pflanzliches Arzneimittel“ ermöglicht. Innerhalb dieser Gesetzgebung wurde der regulatorische 
Status für Myrrhinil-Intest® angepasst und eine Registrierung angestrebt, woraufhin Belege 
gemäß der Anforderungen der Richtlinie zur Verfügung gestellt werden müssen. Ein Aspekt 
dieser Anforderungen umfasst Belege zur Plausibilität der pharmakologischen Wirkung oder 
Wirksamkeit (Richtlinie 2004/24/EG § 16a). Begleitend hierzu müssen diese Informationen 
durch robuste präklinische Daten untermauert werden. 
Ziel der vorliegenden Arbeit war es, das pharmakologische Profil des pflanzlichen 
Arzneimittels Myrrhinil-Intest® zu aktualisieren, indem die pharmakologische Wirkung der 
Einzelkomponenten mit Hilfe biochemischer und pharmakologischer Methoden untersucht 
wird. 
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In diesem Zusammenhang sollten im Einzelnen die spasmolytischen und anti-
inflammatorischen Wirkungen der Komponenten untersucht werden, da diese hauptsächlich 
zu den beschriebenen klinischen Effekten beizutragen scheinen. 
Für die Durchführung der Experimente wurden Auszüge aus Myrrhe und Kaffeekohle 
hergestellt, um applikationsfähige Testsubstanzen zu erhalten. Der Kamillenblüten-
Trockenextrakt, welcher in der fertigen Darreichungsform verwendet wird, ist nach Lösung in 
Ethanol oder DMSO gebrauchsfertig. Ein wässriger Kaffeekohle-Auszug wurde nach 
Extraktion mit gereinigtem Wasser und anschließender Lyophilisation hergestellt. Durch 
Extraktion mit gereinigtem Wasser bzw. Ethanol und anschließender Lyophilisation wurden die 
wasser- bzw. ethanollöslichen Fraktionen des Myrrheharzes getrennt und ein wässriger sowie 
ein ethanolischer Myrrhe-Extrakt hergestellt. 
Die spasmolytische Aktivität wurde an isolierten Dünndarmpräparaten der Ratte unter 
Verwendung isometrischer Kontraktionsmessungen untersucht. 
Myrrheharz und Kamillenblüten zeigten spasmolytische Aktivität, während Kaffeekohle keinen 
spasmolytischen Effekt induzierte. Die spasmolytische Wirkung von Myrrhe ist stark 
ausgeprägt und wird durch eine Hemmung von L-Typ Calciumkanälen vermittelt. Hierbei treten 
kompetitive antagonistische Effekte in niedrigeren Konzentrationen auf, welche in höheren 
Konzentrationen durch nicht-kompetitive antagonistische Effekte überlagert werden. 
Für die Untersuchungen zur anti-inflammatorischen Aktivität wurde ein TNBS-
Entzündungsmodell genutzt. Die Entzündung wurde in vitro in isolierten Dünndarmpräparaten 
der Ratte induziert und der Einfluss der Pflanzenextrakte auf Kontraktilität, Morphologie und 
TNFα-mRNA-Expression untersucht. Diese Parameter wurden unter Verwendung 
isometrischer Kontraktionsmessung, histologischer Untersuchungen bzw. TNFα-
Genexpressionsanalyse bestimmt. 
Weiterführend wurde ein LPS-Entzündungsmodell verwendet. Hierbei wurde LPS als pro-
inflammatorischer Stimulus genutzt, um Makrophagen bzw. Makrophagenähnliche zu 
aktivieren und anschließend den Effekt der Extrakte auf die Zytokinausschüttung zu 
untersuchen. 
Kamillenblüten-Extrakt induzierte einen deutlichen anti-inflammatorischen Effekt, welcher 
sowohl im TNBS- als auch im LPS-Entzündungsmodell sichtbar war. 
Die anti-inflammatorische Aktivität von Myrrheharz bietet ein komplexeres Bild. Der wässrige 
Myrrhe-Extrakt zeigte im TNBS-Entzündungsmodell anti-inflammatorische Effekte. Er hemmte 
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den TNBS-induzierten Kontraktilitätsverlust sowie die morphologische Schädigung und 
Überexpression von TNFα-mRNA. Auf die LPS-induzierte Freisetzung von TNFα aus 
makrophagenähnlichen Zellen hatte er jedoch keinen Einfluss. 
Der ethanolische Myrrhe-Extrakt führte zu einer deutlichen Verminderung der LPS-induzierten 
Freisetzung von TNFα und Stickstoffmonoxid. Im TNBS-Entzündungsmodell konnte jedoch 
kein Effekt beobachtet werden. 
Die anti-inflammatorische Aktivität von Kaffeekohle in den verwendeten Modellen ist von 
geringerer Wirkkraft. Lediglich im LPS-Entzündungsmodell wurde in höheren Konzentration 
die LPS-induzierte Freisetzung von TNFα vermindert. 
Um nähere Informationen zu den zugrundeliegenden Mechanismen der beobachteten Effekte 
zu erhalten, wurde eine Mikroarray-Genexpressions-Analyse durchgeführt. Hierbei wurde der 
Effekt der Pflanzenextrakte auf das Genexpressionsprofil nativer humaner Makrophagen 
untersucht. Als pro-inflammatorische Stimuli wurden LPS und Interferon-y (IFNγ) verwendet. 
Kamillenblüten und Kaffeekohle beeinflussten das Genexpressionsprofil unter LPS/IFNγ-
Stimulation deutlich. Dagegen führte weder ethanolischer noch wässriger Myrrhe-Extrakt unter 
LPS/IFNγ-Stimulation zu einer deutlichen Beeinflussung der Expression von Genen, die mit 
Entzündungsprozessen in Verbindung stehen. Wässriger Myrrhe-Extrakt  führte jedoch an 
unstimulierten Zellen zu einer vergleichbaren Veränderung des Genexpressionsprofils wie 
nach LPS/IFNγ-Stimulation, was als Hinweis auf einen immunstimulierenden Effekt gewertet 
werden kann. 
Die vorliegenden Untersuchungen zeigen das pharmakologische Potenzial der Komponenten 
des pflanzlichen Arzneimittels in Bezug auf ihre spasmolytische und anti-inflammatorische 
Aktivität. Es konnte nachgewiesen werden, dass die pflanzlichen Inhaltsstoffe spasmolytische 
und anti-inflammatorische Effekte induzieren, welche für die Behandlung von 
gastrointestinalen Beschwerden von Bedeutung sind und die beschriebene klinische 
Wirksamkeit des Präparates untermauern. 
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